

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, 15/57, 15/67, 15/85, 9/64, C07K 14/72, C12Q 1/68, A61K 48/00		A1	(11) International Publication Number: WO 00/49147
			(43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/EP00/01368		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 February 2000 (18.02.00)			
(30) Priority Data: 199 07 099.7 19 February 1999 (19.02.99) DE 60/120,848 19 February 1999 (19.02.99) US			
(71) Applicant (for all designated States except US): THERAGENE BIOMEDICAL LABORATORIES GMBH [DE/DE]; Am Klopferspitz 19, D-82152 Martinsried (DE).			
(72) Inventor; and (75) Inventor/Applicant (for US only): HAUSER-FUNKE, Charlotte [DE/DE]; Romanstr. 95, D-80369 München (DE).			
(74) Agents: HELBING, Jörg et al.; von Kreisler Selting Werner, Deichmannhaus am Dom, D-50667 Köln (DE).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: HORMONE-HORMONE RECEPTOR COMPLEXES AND NUCLEIC ACID CONSTRUCTS AND THEIR USE IN GENE THERAPY



(57) Abstract

The invention relates to the use of a nucleic acid construct comprising at least one hormone responsive element and a transgene for preparing an agent for gene transfer. It further relates to particular nucleic acid constructs comprising at least one hormone responsive element and a transgene, wherein one of said at least one hormone responsive elements is not functionally linked to the transgene, vectors comprising such nucleic acid constructs and compositions of matter comprising such nucleic acid constructs wherein the hormone responsive elements of the constructs are coupled to a hormone-hormone receptor complex. The nucleic acid constructs, plasmids, and compositions of matter of the invention have applications in gene therapy, particularly in the treatment of human blood clotting disorders, such as hemophilia. They may also be used to up- or down-regulate target genes and for the delivery of vaccines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Hormone –Hormone Receptor Complexes and Nucleic Acid Constructs and Their Use in Gene Therapy

5

Background of the Invention

1. Object of the Invention

The invention relates to the use of a nucleic acid construct comprising at least one hormone responsive element and a transgene for preparing an agent for gene transfer. It further relates to particular nucleic acid constructs comprising at least one hormone responsive element and a transgene, wherein one of said at least one hormone responsive elements is not functionally linked to the transgene, vectors comprising such nucleic acid constructs and compositions of matter comprising such nucleic acid constructs wherein the hormone responsive elements of the constructs are coupled to a hormone-hormone receptor complex. The nucleic acid constructs, plasmids, and compositions of matter of the invention have applications in gene therapy, particularly in the treatment of human blood clotting disorders, such as hemophilia. They may also be used to up- or down-regulate target genes and for the delivery of vaccines.

2. Summary of the Related Art

Gene therapy is a method that holds great promise for many diseases and disorders. In general, it involves the transfer of recombinant genes or transgenes into somatic cells to replace proteins with a genetic defect or to interfere with the pathological process of

an illness. In principle, gene therapy is a simple method. In practice, many disadvantages must still be overcome.

Research in gene therapy has concentrated on ways to most effectively incorporate DNA into cells of a patient. Viral vectors are currently the widely used vehicles in clinical gene therapy approaches. In terms of efficacy in gene expression, the viral delivery systems have major advantages over techniques using DNA-lipid formulations as delivery vehicles or over mechanical methods, such as the gene gun. Although there are a variety of viral systems tested for gene therapeutical strategies, retroviral vectors and adenoviral vectors are presently the most widely used vehicles (Salmons, B. and Gunzburg, W. H., *Hum. Gene Ther.*, Vol. 4, 129, 1993; Kasahara, N. A., et al., *Science*, Vol. 266, 1373, 1994; Ali, M., et al., *Gene Ther.*, Vol. 1, 367, 1994.). Still, these systems have major disadvantages, such as potential viral contamination. Other safety concerns continue to hamper the development of clinical application of gene therapy using these viral systems. For example, recombinant retroviruses have the disadvantage of random chromosomal integration, which may lead to activation of oncogenes or inactivation of tumor-suppressor genes. Also, repetitive use of recombinant adenoviruses has caused severe immunological problems (Elkon, K. B. et al., *Proc. Natl. Acad. Sci. USA*, Vol. 94, 9814, 1997). The humoral response resulted in the production of antibodies to adenovirus proteins preventing subsequent infection. Immunosuppressive drugs may ameliorate these effects, but they place an additional burden on the patient (Dai, Y., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 92, 1401, 1995).

Yet another viral delivery system involves adenoassociated virus (AAV). The AAV requires coinfection with an unrelated helper virus. Although such recombinant AAV virions have proven useful for introducing several small gene sequences into host cells, gene

delivery systems based on those particles are limited by the relative small size of AAV particles. This feature greatly reduces the range of appropriate gene protocols. Moreover, the need to also use a helper virus adds a complicating factor to this delivery system (Muzyczka, N.,
5 Curr. Top. Microbiol. Immunol., Vol. 158, 97, 1992).

Though safer, non-viral gene therapy approaches are also unsatisfactory. Problems with inefficient gene delivery or poor sustained expression are major drawbacks. Yet the methods available such as the direct injection of DNA into cellular compartments, or the
10 application of mixtures of DNA with cationic lipids or polylysine allowing the transgene to cross the cell membrane more easily, have not overcome these hurdles (Felgner, P., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 84, 7413, 1987; Behr, J.-P., *Bioconjugate Chemistry*, Vol. 5, 382, 1994).

15 Introduction of naked DNA (polynucleotide) sequences (including antisense DNA) into vertebrates, is reported to be achieved by injection into tissues such as muscle, brain or skin or by introduction into the blood circulation (Wolff, J. A., et al., *Science*, Vol. 247, 1990; Lin, H., et al., *Circulation*, Vol. 82, 2217, 1990; Schwartz, B., et al.,
20 *Gene Ther.*, Vol. 3, 405, 1996). Also, a direct gene transfer into mammals has been reported for formulations of DNA encapsulated in liposomes and DNA entrapped in proteoliposomes containing receptor proteins. Although injected naked DNA leads to transgene expression, the efficiency is by far not comparable to viral-based DNA delivery
25 systems. A limitation of the method of naked DNA injection is the fact that transgene expression is dose-dependent. The gene expression is saturable, and an increase in the amount of DNA injected leads to decreased protein production per plasmid. Thus, protein expression can dramatically decrease, if the amount of DNA injected is above a
30 certain threshold.

Among the genetic disorders that the skilled artisan has sought to overcome using these prior art methods are those relating to blood clotting disorders, and in particular, hemophilia (Lozier, J. N. and Brinkhous, K. M., *JAMA*, Vol.271, 1994; Hoebe, R. C., *Biologicals*, Vol. 23, 27, 1995). For example, hemophilia A and B are X-linked, recessive bleeding disorders caused by deficiencies of clotting factors VIII and IX, respectively (Sadler, J. E. et al., in: *The Molecular Basis of Blood Diseases*, 575, 1987). The incidence of hemophilia is about 1 in 5,000 male births. Hemophiliacs suffer from excessive bleeding due to the lack of clotting at the site of wounds. The inability to clot properly causes damage to joints and internal tissues as well as posing risks to the proper treatment of cuts.

Treatment of hemophilia A is possible by the administration of the blood clotting factor VIII. Until recently, factor VIII preparations had to be prepared by concentrating blood from donors, posing the risk of contamination by infectious agents, such as HIV and hepatitis. The gene for factor VIII has been cloned (e.g., Vehar et al., *Nature* Vol. 312, 337 1984) allowing for the production of a recombinant product. Although recombinant methods provide factor VIII of higher purity than blood concentrates, the exogenous supply of factor VIII to a patient still requires repeated doses throughout the lifetime of the patient, an inconvenient and expensive solution.

Other forms of hemophilia include hemophilia B, caused by a defect in the gene coding for Factor IX. The gene therapy systems described above have been attempted for the treatment of hemophilia A and B with factors VIII and IX, respectively. (See e.g., WO 94/29471). However, these systems have the disadvantages already discussed above.

On the other hand, the classical model of the action of hormones is based on the concept of binding interaction of the hormone to an

intracellular receptor, located in the cytoplasm or the nucleus (Evans, R., *Science*, Vol. 240, 889, 1988). These intracellular receptors remain latent until exposed to their target hormone. When so exposed, the hormone receptor changes its conformation after the hormone is bound and translocates in the activated form into the cell nucleus where it binds as a dimer to hormone responsive elements in the promoter region of hormone-regulated genes (Beato, M., *Cell*, Vol. 56, 335, 1989; O'Malley, B., et al., *Biol. Reprod.*, Vol. 46, 163, 1992). The hormone responsive elements are enhancer elements usually located in the 5' flanking region of the specific hormone-induced gene, i.e., are functionally linked to the specific hormone induced gene. DNA constructs comprising a hormone responsive element and a nucleic acid sequence encoding a protein of interest are disclosed in U.S. Pat. Nos. 5,688,677 and 5,580,722 and are taught to be suitable for expression of the protein of interest.

An example of such intracellular receptors is the steroid receptor. Steroid receptors belong to a superfamily of ligand-dependent transcription factors characterized by a unique molecular structure. The centrally located highly conserved DNA-binding domain defines this superfamily. The second important and relatively invariant region is the COOH-terminal ligand-binding domain. An example of such a receptor is the progesterone receptor mediated by the steroid progesterone. At the progesterone receptor, progesterone acts as a natural agonist whereas it displays potent antimineralocorticoid properties both at the molecular and the systemic level. Besides classical effects on the uterus, antiepileptic, anxiolytic, hypnotic and anesthetic properties have been attributed to progesterone according to numerous studies.

Methods have been proposed for the use of mutant hormone receptors, including mutant steroid receptors for gene therapy. For

example, such methods are disclosed in WO 93/23431, WO 98/18925, WO 96/40911. Moreover, WO 98/33903 discloses a genetic construct comprising a steroid responsive element from a tissue specific gene, a coding sequence, and an SV40 enhancer.

5

Brief Description of the Invention

The object of the present invention is to overcome the disadvantages of the previous gene therapy delivery systems. It was found that a hormone-hormone receptor complex possesses the ability to drag a nucleic acid construct having one or more hormone responsive element(s) through the cell membrane into a cell. It was also found that if the construct comprises further functional sequences besides the hormone responsive elements (hereinafter "transgenes"), the functional sequences exert their function. The hormone responsive element may also enhance the expression of the transgene. Moreover, it was found that steroid hormones are very effective mediators for the transfer of nucleic acid constructs through the cell membranes into a cell. The present invention thus provides

(1) the use of a nucleic acid construct comprising at least one hormone responsive element (hereinafter referred to as "HRE") and a transgene for preparing an agent for gene transfer (said at least one HRE being functionally linked to the transgene or not);

(2) a preferred embodiment of (1) above, wherein the agent further comprises a hormone-hormone receptor complex;

(3) a nucleic acid construct comprising at least one HRE and a transgene, wherein one of said at least one HREs is not functionally linked to the transgene;

(4) a vector comprising the nucleic acid construct of (3) above;

(5) a transformed cell or transgenic organism comprising the nucleic acid construct as defined in (3) above or the vector as defined in (4) above;

(6) a composition of matter comprising a nucleic acid construct
5 comprising at least one HRE and a transgene as defined in (3) above and/or a vector as defined in (4) above, said at least one HRE being coupled to a hormone-hormone receptor complex;

(7) a preferred embodiment of (6) above, wherein the transgene is a gene encoding a blood clotting factor;

10 (8) a preferred embodiment of (7) above, wherein the blood clotting factor is factor IX;

(9) a preferred embodiment of (7) above, wherein the blood clotting factor is factor VIII;

(10) a pharmaceutical composition comprising the nucleic acid
15 construct as defined in (3) above and/or the composition of matter as defined in (6) to (9) above;

(11) a method for preparing the composition of matter as defined in (6) above, which method comprises admixing the nucleic acid construct with the hormone receptor and the hormone;

20 (12) a method for gene transfer which comprises administering the agent as defined in (1) and (2) or the composition of matter as defined in (6) to (9) above to an organism or to a cellular system;

(13) a method for delivering into an organism or into a cellular system a nucleic acid encoding a transgene to be expressed in the
25 cells of the organism or the cells of the cellular system, which method comprises administering an agent as defined in (1) above or composition of matter as defined in (6) to (9) above to the organism or to the cellular system so that the hormone in the composition interacts with the cell membrane and therewith enhances diffusion

and transport of the nucleic acid that is coupled to the hormone-hormone receptor complex across the membrane and into the cell;

(14) a method of treating blood clotting disorders comprising administering a therapeutically effective amount of the composition of matter as defined in (7) above to an organism or to a cellular system;

(15) a method of treating hemophilia B, comprising administering a therapeutically effective amount of the composition of matter as defined in (8) above to an organism or to a cellular system;

(16) method of treating hemophilia A, comprising administering a therapeutically effective amount of the composition of matter as defined in (9) above to an organism or to a cellular system;

(17) use of a steroid hormone for preparing an agent for gene transfer; and

(18) a method for gene transfer which comprises administering a nucleic acid construct to an organism or to a cellular system, wherein the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone.

In a preferred embodiment of (1) to (16) above the hormone responsive element is a steroid responsive element (SRE), most preferably a progesterone responsive element (PRE). In embodiments (2) and (6) to (16) the receptor preferably is a steroid receptor, most preferably, a progesterone receptor. Similarly, the hormone is preferably a steroid, most preferably, progesterone.

The present invention thus provides a delivery system for gene therapy that should overcome the prior art disadvantages. The presence of the hormone responsive element on the nucleic acid carrying a transgene encourages the binding of a hormone-hormone receptor complex. Thus, the present invention uses the activated hormone receptor as a link (or binding compound) between the

nucleic acid carrying the transgene and the hormone known to interact with the cell membrane. The general known biological activity mediated by the HREs is not the primary effect utilized in the present invention, but might be an additional effect when regulation of the transgene is desired. The general principle is depicted in Figure 1. The hormone responsive element is preferably present as a nucleic acid dimer sequence or nucleic acid multimer sequence. Even in an inverse orientation, the hormone responsive element will exert its proper function. The hormone-hormone receptor complex contains a hormone receptor that becomes activated after binding of its specific hormone. The hormone receptor in the activated state is able to recognize and bind to its specific hormone responsive element, which in the present invention is present within the nucleic acid comprising the desired transgene, e.g., a human blood-clotting factor.

Vaccination is another aspect of the embodiment (12) defined above. Introducing a nucleic acid construct or composition of matter of the invention comprising a gene for an antigen or containing a viral sequence into a cell (DNA vaccines) using the method mentioned above may also provide a way to stimulate the cellular immune response.

Brief Description of the Drawings

Figure 1 shows the concept of gene transfer of the present invention (with HRE = hormone responsive element, HR = hormone receptor, H = hormone, blank circles = lipophilic matrix).

Figure 2 is a diagram of the vector pTGFG1.

Figure 3 is a diagram of the vector pTGFG5.

Figure 4 is a diagram of the vector pTGFG20.

Figure 5 is a diagram of the vector pTGFG33.

Figure 6 is a diagram of the vector pTGFG36.

Figure 7 is a diagram of the vector pTGFG53.

Figure 8 is a diagram of the vector pTGFG64.

Figure 9 is the DNA sequence of vector pTGFG36 (SEQ ID NO: 1).

5 Figure 10 shows the protein sequence of factor IX encoded by vector pTGFG36 (SEQ ID NO: 2).

Figure 11 shows a GFP concentration curve for cell homogenates after transfection with pTGFG5 and pTGFG20, respectively.

10 Figure 12 shows corresponding light (a and c) and fluorescent (b and d) micrographs of HeLa cells transfected with pTGFG5 (a and b) and pTGFG20 (c and d), respectively.

Figure 13 shows the amount of GFP expressed by utilizing the favoured vectors of the invention in a transfection experiment.

15 Relative fluorescence units from mock and background can be clearly separated.

Figure 14 shows the additive effect of human clotting factor IX on clotting activity of mouse blood.

20 Figure 15: hPR (A-form) was expressed in insect cells and purified by cobalt²⁺ affinity chromatography as described in Example 5. The final preparation (85µg protein) was separated on a denaturing 7,5% SDS-polyacrylamid gel, followed by staining with coomassie® R250 (lane A) or western blotting with hPR-specific staining (lane C).

25 Lane B: Molecular mass standard. Arrows indicate the two highly enriched protein species (94 and 74 kDa) accessible to immunodetection.

Figure 16: Domain structure of hPR-B (numbers on the top of the bar represent amino acid positions within the polypeptide sequence).

Figure 17 shows the mean values of the difference in the clotting time of Example 9.

30 Figure 18 shows the clotting time detected in Example 9.

Figure 19 shows the activity of human progesterone receptor as determined in Example 8.

Figure 20: shows the amino acid sequence of the hPR B-Form. The start methionine 165 of the hPR A-Form is underlined (SEQ ID NO: 18).

Figure 21 shows the nucleic acid sequence of the mRNA coding for hPR. The reading frame for the hPR B-form starts at position 176, the reading frame for the hPR A-Form at position 668. The respective start codons ATG are underlined (SEQ ID NO: 19). The sequences of Figures 20 and 21 are taken from Genbank, accession number AF016381.

Detailed Description of the Invention

1. Definitions

"Nucleic acid" means DNA, cDNA, mRNA, tRNA, rRNA. The nucleic acid may be linear or circular, double-stranded or single-stranded.

"Nucleic acid construct" refers to a composite of nucleic acid elements in relation to one another. The nucleic acid elements of the construct may be incorporated into a vector in such an orientation that a desired gene may be transcribed, and if desired, a desired protein may be expressed.

"Transgene" refers to a functional nucleic acid sequence which is transcriptionally active (with or without regulatory sequences).

"Gene transfer" includes "gene therapy".

"Hormone responsive element" (HRE) refers to regions of nucleic acids, and in particular, DNA, which regulate transcription of genes in response to hormone activation. HREs are typically about 10-40 nucleotides in length, and more usually, about 13-20 nucleotides in

length. As explained above, HREs become activated when a hormone binds to its corresponding intracellular receptor causing a conformational change, so that the receptor has increased affinity for the HRE and binds to it. The HRE, in turn, stimulates transcription. A
5 "steroid responsive element" (SRE) is an HRE that regulates transcription of genes in response to steroid activation. A "progesterone responsive element" (PRE) is an HRE/SRE that regulates transcription of genes in response to progesterone activation.

10 A "hormone receptor" refers to a receptor which binds to and is activated by a hormone. A "steroid receptor" refers to a receptor which binds to and is activated by a steroid hormone. A "progesterone receptor" is a receptor which binds to or is activated by the steroid hormone progesterone.

15 "Functionally linked" refers to configurations of the nucleic acid construct, where the HRE (or SRE/or PRE) is located within the construct so that it can stimulate transcription of the transgene. "Not functionally linked" refers to configurations where the HRE is so remotely located from the transgene that it cannot stimulate its
20 transcription.

"Gene" refers to DNA sequence encoding a polypeptide, optionally including leader and trailer sequences and introns and exons.

25 "Vector" refers to any genetic construct, such as a plasmid, phage, cosmid, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. The term includes cloning and expression vehicles.

"Promoter" refers to a region of regulatory DNA sequences for
30 the control of transcription of a gene to which RNA polymerase binds.

The promoter forms an initiation complex with RNA polymerase to initiate and drive transcription activity. "Enhancers" may activate the complex or "silencers" may inhibit the complex. A "tissue-specific promoter" is a promoter found in the DNA of tissue for transcription of genes expressed in this specific tissue.

"Organism" refers to a multicellular living entity including vertebrates such as mammals (especially humans, cattle, rodents, dogs) and invertebrates.

"Cellular system" includes cell cultures, e.g., primary cell cultures (especially those suitable for reimplantation), stem cells, blood cells, tissue samples and whole organs and immortalized cell cultures.

"Therapeutically effective dose" of the products of the invention refers to a dose effective for treatment or prophylaxis, for example, a dose that yields effective treatment or reduction of the symptoms of hemophilia. It is also a dose that measurably activates expression of a target gene as determined by measurements of target protein levels, or a dose that is predictable to be effective for treatment or prophylaxis by extrapolating from *in vitro* or *in vivo* data. The determination of a therapeutically effective dose is within the purview of one skilled in the art.

"Encodes" or "encoding" refers to a property of the nucleic acid sequence of being transcribed (in case of DNA) or translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences.

For the purposes of this application, "express", "expressing" or "expression" shall refer to transcription and translation of a gene encoding a protein.

2. Detailed Description and Examples

As stated above, an object of the present invention is to provide a new and improved delivery system for gene therapy. The invention thus provides nucleic acid constructs comprising at least one HRE and a transgene wherein one of said at least one HREs is not functionally
5 linked to the transgene, and compositions of matter comprising such nucleic acid construct wherein said at least one HRE is coupled to a hormone-hormone receptor complex (embodiments (3) and (6) defined above). A preferred embodiment of the nucleic acid construct
10 and of the composition of matter of the invention is one where the hormone responsive element is a steroid responsive element (SRE), and the receptor is a steroid receptor. Most preferably, the hormone responsive element is a progesterone responsive element (PRE), and the receptor is a progesterone receptor.

15 Potential HREs for use in the present invention have been previously described. For example, GREs (Scheidereit, C., et al., *Nature*, Vol. 304, 749, 1983; von der Ahe, D., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 83, 2817, 1986), EREs or PREs (Chambon, P., et al., *Rec. Prog. Horm. Res.*, Vol., 40, 1, 1984; Klock, G., et al., *Nature*,
20 Vol. 329, 734, 1987). As already stated above, the most preferred HRE for the invention is a PRE. Specifically, the preferred PRE is described in Example 1, i.e., is the double stranded DNA sequence comprised of SEQ ID NOs: 3 and 4. The nucleic acid for use in the invention comprises at least one hormone responsive element.
25 Preferred is a nucleic acid comprising more than one HRE. For example, the nucleic acid may comprise three to ten, preferably three to five HREs. The most preferred embodiment is a nucleic acid comprising three to five PREs.

Potential hormone receptors for use in the present invention
30 are, for example, estrogen receptors, mineralocorticoid receptors,

glucocorticoid receptors, retinoic acid receptors, androgen, calcitriol, thyroid hormone or progesterone receptors and orphan receptors. Such receptors have been previously described. (Green, S., et al., *Nature*, Vol. 320, 134, 1986; Green, G. L., et al., *Science*, Vol. 231, 1150, 1986; Arriza, J. L., et al., *Science*, Vol. 237, 268, 1987; Hollenberg, S. M., et al., *Nature*, Vol. 318, 635, 1985; Petkovitch, M., et al., *Nature*, Vol. 330, 444, 1987; Giguere, V., et al., *Nature*, Vol. 330, 624, 1987; Tilley, W., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 86, 327, 1989; Baker, A. R., et al., *Proc. Natl. Acad. Sci. USA*, Vol. 85, 3294, 1988; Weinberger, C., et al., *Nature*, Vol. 324, 641, 1986; Sap, J., et al., *Nature*, Vol. 324, 635, 1986; Misrahi, M., et al., *Biochem. Biophys. Res. Commun.*, Vol. 143, 740, 1987; Kastner, P., et al., *Cell*, Vol. 83, 859, 1995). These receptors may be from human or other mammalian sources, although human is preferred. Nucleotide and/or amino acid sequences of human steroid receptors are available in the GenBank: mineralocorticoid receptor: M16801; glucocorticoid receptor α : M10901; glucocorticoid receptor α_2 : U01351; glucocorticoid receptor β : M11050; retinoic acid receptor α : AF088888 (exon 1), AF088889 (exon 2), AF088890 (exon 3), AF088891 (exon 4), AF088892 (exon 5 and 6), AF088893 (exon 7), AF088894 (exon 8), AF088895 (exon 9 and complete cDNA); retinoic acid receptor γ : M24857; androgen receptor: M27423 (exon 1), M27424 (exon 2), M27425 (exon 3), M27436 (exon 4), M27427 (exon 5), M27428 (exon 6), M27429 (exon 7), M27430 (exon 8); thyroid hormone receptor α_1 : M24748, thyroid hormone receptor α_2 : J03239; progesterone receptor: AF016381; somatotropin receptor: J00148; vitamin D receptor (calcitriol receptor): J03258.

The skilled person will understand that expression of the receptor proteins can be achieved by standard methods, e.g. via PCR-cloning of the known cDNAs from cDNA libraries and overexpression of

the corresponding proteins in suitable expression vectors, such as, for example, the vectors of the present invention, in suitable host cells, e.g., COS cells. Accordingly, subsequent purification of the cytosolic fraction can be achieved by routine methods such as affinity chromatography purification. For this purpose, various suitable antibodies against the desired receptor are commercially available. For example, polyclonal antibodies against the mouse progesterone receptor that have a sufficiently high cross-reactivity for the human protein are available from Dianova (Hamburg, Germany). Likewise, further purification can be achieved by standard methods, e.g., chromatographical methods such as ion-exchange chromatography and/or FPLC.

The most preferred receptor is the progesterone receptor. Preferably, the receptor is a human progesterone receptor. Such a human progesterone receptor (from T47D human breast cancer cells) is disclosed in US Patent No. 4,742,000, and cells expressing this receptor have been deposited (ATCC deposit number HTB, 133). As already described above, it would be routine to purify such a receptor from the cytosol using receptor specific antibodies. In addition, US Patent No. 4,742,000 discloses a method for purification of the human progesterone receptor using a specific steroid affinity resin (cf. Grandics et al., Endocrinology, Vol. 110, 1088, 1982).

Briefly, the cytosolic fraction of the T47D cells is passed over Sterogel, a commercial preparation of deoxycorticosterone coupled to Sepharose® 2B that selectively binds the progesterone receptor. After washing with loading buffer, the bound receptor is eluted with a buffer containing progesterone. The eluted steroid-receptor complex is then chromatographed on DEAE-Biogel and eluted stepwise with a buffer containing 0.2M NaCl. Subsequently, the bound progesterone can be

readily exchanged. As described above, further purification can be achieved by routine methods well-known to the skilled person.

An alternative method is disclosed in Example 5.

The structure of the hPR polypeptide is depicted in Fig. 16. The hPR polypeptide is composed of distinct structural domains. Naturally the human progesterone receptor (hPR) is expressed as two different sized proteins termed hPR-B (120 kDa) and hPR-A (94 kDa). HPR-A is a truncated but otherwise identical form of hPR-B, that is missing 165 the N-terminal amino acids (see Fig. 20, SEQ ID NO: 18). Both forms seems to be indistinguishable regarding their progesterone or DNA binding properties. In human cells the A and B forms of hPR are produced from the same gene by alternate initiation of translation at two different AUG start sites within the same RNA transcript. As it was reported earlier hPR-A and B can be expressed in *Spodoptera frugiperda* (Sf9) cells as biological fully active polypeptides (Christensen *et al.*, Mol. Endocrinol. 5, 1755ff (1991); Elliston *et al.*, JBC 267, 5193-5198 (1992)).

The carboxyl terminus of the hPR polypeptide as shown in Fig. 16 comprises a progesterone binding domain (PBD) but also contains sequences responsible for the association with heat shock proteins and receptor dimerization. The hinge region provides a flexible link between the DNA-binding domain (DBD) and the PBD but is also thought to contain elements for receptor dimerization as well as nuclear localization. Binding of the hPR to its corresponding target sites at the chromosomal DNA (PREs, Progesterone Responsive Elements) is known to be mediated by the DBD. The remaining N-terminal trans-activation domain (TAD) consists of regions specific for the *in vivo* function of the hPR as a transcriptional gene activator.

Even though the N-terminus also seems to contribute directly to the homodimerization of hPR after progesterone binding, it has been

demonstrated that a fragment comprising only the hinge region and the PBD was the minimal C-terminal fragment to mediate progesterone dependent hPR-hPR-interaction (Tetel *et al.*, Mol. Endocrinol. 11, 1114ff. (1997). It is believed that genetically engineered hPR polypeptides lacking either in part or completely the TAD (amino acids 1 to 556) might be expressed as structurally stable and fully soluble dimers in the presence of progesterone. Complexes with such a truncated hPR (provided that said truncated hPR exhibits DNA-binding activity as well as progesterone-binding activity) may functionally replace the complexes with the full length form of the described recombinant hPR-A or hPR-B proteins, since still mediating the contact between the plasmid DNA and the progesterone. Thus, the hPR in embodiments (2) and (6) to (16) of the invention preferably is a PR comprising nucleic acids 557 to 933 of natural hPR shown in SEQ ID NO: 18.

Effective expression of such a truncated version of hPR is possible in the baculovirus system but also in other eukaryotic expression systems, such as cultivated mammalian cells or yeast cells. Furthermore, also an *E. coli* overexpression strain is a possible system for the production of those polypeptides. In this case, the fusion of such a truncated hPR-version to a suitable polypeptide sequence, e.g. a histidine containing sequence or the GST (glutathion S- transferase) protein, might be helpful to overcome insolubility problems as well as to facilitate the isolation and purification of the expressed protein.

Mutated versions of these receptors and derivatives thereof, that still retain the function of the receptors to bind a ligand and thereby become activated and bind DNA and regulate transcription, may also be employed in the invention. Such derivative may be a chemical derivative, variant, chimera, hybrid, analog, or fusion.

The third component of the gene transfer system of the invention is the hormone. The hormone in the agent of embodiment 2 and in the composition of matter of embodiment (6) include synthetic and natural hormones, preferably steroid hormones, such as estrogen, testosterone, glucocorticoid, androgen, thyroid hormone, and progesterone or derivatives thereof. These are widely available. Progesterone is most preferred. For example, natural micronized progesterone is the preferred progesterone from which has been marketed in France since 1980 under the trademark of UTROGESTAN® and is still available in Germany under the trademark UTROGEST®. Its properties are similar to the endogenous progesterone, in particular, it has antiestrogen, gestagen, slightly antiandrogen and antimineralocorticoid properties. The natural micronized progesterone in said marketed products is dispersed in a matrix as described hereinbelow.

The above micronized progesterone has advantages that make it a suitable carrier for genes or nucleic acid constructs to target cells. Specifically, the synergistic effect of the double process of micronization and suspension in long-chain fatty acids residues of an oil results in increasing progesterone absorption. It has been demonstrated that after oral administration of 100 mg of UTROGESTAN®, peak plasma progesterone levels were obtained after 1-4 hours in most cases (Padwick, M. L., et al., *Fertil. Steril.*, Vol. 46, 402, 1986). Later on, the levels declined substantially, although they were still elevated at 12 hours. Even at 84 hours the levels were slightly higher than baseline. A U.S. kinetic study confirmed earlier work demonstrating the bioavailability of oral micronized progesterone. They showed a peak effect at 2 hours followed by rapid decrease in plasma progesterone level (Simon, J. A., et al., *Fertil. Steril.*, Vol., 60, 26, 1993).

A further advantage of using progesterone as a carrier is the low level of disadvantageous side effects. Orally administered progesterone adversely affects neither plasma lipids (Jensen, J. et al., Am. J. Obstet. Gynecol., Vol. 156, 66, 1987) nor carbohydrate metabolism (Mosnier-Pudar, H. et al., Arch. Mal. Coeur, Vol 84, 1111, 1991). Further, progesterone does not affect liver enzymes (ASAT, ALAT, AFOS), sex-hormone binding-globulin (SHBG) synthesis or HDL-cholesterol levels at daily doses of 200 mg and 300 mg. Although the plasma levels of deoxycorticosterone may increase substantially during UTROGESTAN® treatment, there are strong indications that the mineralocorticoid effects of this progesterone metabolite are completely counteracted by the anti-mineralocorticoid effects of progesterone itself. This is apparent from a comparative study (Corvol, P., et al., In: Progesterone and progestins. Raven Press, New York, 179, 1983) in which oral UTROGESTAN® was capable of antagonizing the mineralocorticoid effects of 9- α -fluorohydrocortisone.

In the agent of embodiment (2) and in the composition of matter of embodiment (6) of the invention the molar ratio of HRE (or SRE/or PRE) within the nucleic acid construct to hormone receptor is preferably from 1:1 to 1:10, more preferably from 1:2 to 1:5. On the other hand, the molar ratio of hormone to hormone receptor is preferably at least 1000:1, more preferably at least 10000:1. Thus, the hormone is present in a large excess relative to the hormone receptor and the HRE, which is desirable in view of the ability of the hormones to transfer nucleic acid constructs through cell membranes.

The skilled artisan will appreciate that the agent of embodiments (1) and (2) and the pharmaceutical composition of embodiment (10) may contain other components capable of assisting in introducing the nucleic acid into a cell for the purpose of gene therapy (matrix compounds). Specifically, the agent and the composition, especially

the hormone component thereof, may contain the following matrix compounds: glucose and related compounds (such as D-sorbitol, D-mannitol); solubilizing adjuvants (such as alcohols, e.g., ethanol); polyhydric compounds such as glycerine, polyethylene glycol and polypropylene glycol; nonionic surface active compounds, ionic surface active compounds such as lecithin; oily compounds such as sesame oil, peanut oil soybean oil, corn oil, etc.; starches and their derivatives such as cyclodextrines and hydroxyalkylated starches; stabilizers such as human serum albumin, preservatives such as benzyl alcohol and phenol; and the like. The preferred matrix contains β -cyclodextrine, glycerine, lecithin and/or corn oil. For example, the pharmaceutical composition of hormone-hormone receptor nucleic acid complex of the invention may be provided orally to humans or animals as a gelatin capsule. Progesterone therein (preferably in micronized form) could be present in a concentration of 50 to 1000 mg, preferably 200 -300 mg dissolved in a 35 % or 40 % β -cyclodextrin solution or in corn oil or glycerol with peanut oil together with lecithin.

Alternatively, when - due to the selection of appropriate matrix components - the pharmaceutical composition is in a pasty, gel-like form, it may be provided topically.

The nucleic acid construct of embodiments (1) to (16) of the present invention may - aside from the transgene and the HREs, SREs, or PREs already disclosed above - further contain promoter, enhancer, and/or silencer sequences. The promoter may be ubiquitous or tissue-specific. Of the ubiquitous promoters, the CMV promoter is most preferred. However, a tissue-specific promoter is preferred over a ubiquitous promoter. For example, the tissue-specific promoters envisioned for the instant invention include α_1 -antitrypsin (further promoters).

The nucleic acid construct may further comprise additional sequences such as the ampicillin resistance gene. Other reporter sequences known to the skilled artisan may also be included, such as, for example, the green fluorescent protein (GFP), luciferase, β -galactosidase or chloramphenicolacetyltransferase (CAT). As an enhancer sequence, the SV40 intron and SV40 Poly A are most preferred. The nucleic acid construct may further contain inducible promoters such as, for example, a MMTV (Mouse Mammary Tumor Virus) promoters inducible via glucocorticoides and Ecdyson-inducible insect promoters.

A preferred nucleic acid construct contains sequentially from the 5' to the 3' end: a PRE, a CMV promoter, a gene of interest, SV40 Intron and SV40 poly A enhancer sequence, and an ampicillin resistant gene. Further PREs are evenly distributed on the vector backbone.

The nucleic acid construct may further contain origin of replication sequences (especially eukariotic origin of replication sequences), elements for gene targeting, integrational sequences (e.g., AAV-ITR, transposon IS), 3'-UTR, "switch" systems (e.g., TET system, Cre/loxP or Flp/ftt system).

The transgene may be chosen from those encoding proteins lacking in a variety of genetic disorders or involved in conditions related to inappropriate responses to hormones, for example, hormone-dependent cancers such as breast, ovarian, and endometrial cancers and prostate cancer. The transgene may also be used to replace a defective gene resulting in such genetic disorders as hemophilia, von Willebrand disease, and cystic fibrosis. The transgene includes mutations of such gene or a gene encoding a fusion product. The nucleic acid construct of the present invention may comprise more than one transgene.

In particular, the transgene may replace genes for a blood clotting factor, and preferably a human blood-clotting factor. The genes encoding factor VIII and factor IX (shown in Fig. 2, SEQ ID NO: 2), involved in hemophilia A and B, respectively, are good candidates
5 for the invention. Other candidates include the gene encoding von Willebrand factor, factor IV, factor X, or protein C.

Other useful transgenes include, but are not limited to, hormone genes such as the genes encoding for insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), α and β seminal inhibins
10 and human growth hormone; hormone receptor genes such as the glucocorticoid receptor, the estrogen receptor, the progesterone receptor, the retinoic acid receptor; growth factors such as vascular endothelial growth factor (VEGF), nerve growth factor, epidermal growth factor; enzyme genes; genes encoding cytokines or
15 lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as α_1 -antitrypsin, and genes encoding substances that function as drugs, e. g., genes encoding the
20 diphtheria and cholera toxins, ricin or cobra venom factor. Also, antisense sequences may be administered as genetic material.

Another aspect of the present invention is vectors comprising the nucleic acid constructs of embodiment (3) of the present invention. These vectors may be used in the composition matter of
25 embodiment (6) of the present invention. Preferably, however, the nucleic acid sequence for use in the invention is circular rather than linear. The vectors may be capable of expressing the nucleic acid in the nucleic acid construct transiently or permanently (including episomally). As noted above, the nucleic acid construct therein may
30 further contain additional elements.

The composition of matter of embodiment (6) of the invention can be prepared by admixing the nucleic acid construct with the hormone receptor and the hormone. Preferably, an aqueous solution of nucleic acid construct was added to the oily suspension containing the hormone at ambient temperature under stirring.

Embodiment(s) of the invention relates to transfected and transformed cells or transgenic organism comprising these vectors and/or nucleic acid constructs. Within the scope of this invention, a transfected cell is one in which foreign DNA has been incorporated. Methods of transfection may include microinjection, CaPO_4 precipitation, electroporation, liposome fusion, or gene gun.

Transformation refers to introducing genetic material into a cell, such as the vectors or nucleic acid constructs of the invention, rendering the cell transiently or permanently altered so that the cell expresses a specific gene product or is otherwise altered in its expression. Transformation may be achieved by *in vivo* or *in vitro* techniques, although *in vivo* transformation is preferred.

A further embodiment of the present invention is pharmaceutical compositions comprising a therapeutically effective dose of the nucleic acid constructs of the invention and a hormone. The hormone is preferably a steroid, and most preferably, progesterone, as described above. The dose is dependent on the condition to be treated, the characteristics of the patient, and the result sought to be achieved. Determining dosage is within the realm of the skilled artisan.

The pharmaceutical composition (or, alternatively, the composition of matter, the nucleic acid construct, or the vector) of the present invention may be administered orally, intravenously, intramuscularly, subcutaneously, topically, through mucosa (including buccal, nasal spray) or by gene gun. Oral administration (of a

micronized hormone dispersion) is preferred. Delivery may be systemic or directed at certain tissue.

The invention further includes a method of introducing into a cell a nucleic acid construct encoding a gene of interest, e.g., a human blood-clotting factor, to express the blood-clotting factor in the cell. In this method, the nucleic acid encoding a human blood-clotting factor is combined with a nucleic acid construct comprising at least one hormone responsive element (HRE), preferably a progesterone responsive element.

The mixture of nucleic acid bound to the hormone-hormone receptor complex together with an excess of hormone, preferably progesterone, will be used to introduce the nucleic acid into a cell by various methods known to the skilled artisan and outlined above. The cell-uptake will be stimulated by the interaction of the hormone with the cell membrane. The hormone or steroid interacts with the lipid bilayer of the cell membrane not only through membrane perturbation but also through activation of certain hormone- or steroid-sensitive membrane receptors. This has been demonstrated for progesterone and other steroids. Last but not least, it is known that hormones are able to cross the cell membrane by diffusion. In the present invention, the nucleic acid bound to the hormone-hormone receptor complex should be transported through the membrane during the process of diffusion or uptake.

Another aspect of the invention is a method of treating a blood clotting disorder by administering a therapeutically effective amount of the composition of matter of the invention to an organism. This method involves the administration and dosage considerations already discussed.

Embodiments (17) and (18) of the invention pertain to the use of a steroid hormone for preparing an agent for gene therapy and/or

gene transfer and to method for gene therapy and/or gene transfer which comprises administering a nucleic acid construct to an organism or to a cellular system, wherein the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone. Suitable steroid hormones are enumerated hereinafter. The preferred steroid hormone in said embodiments of the invention is a natural micronized steroid hormone, in particular a natural micronized progesterone. In a preferred embodiment, the micronized hormone is solubilized/dispersed in a lipophilic matrix as described hereinafter.

Experiments have been performed to illustrate the technical aspects of the present invention. These experiments are described in examples 1 to 9 below. The skilled artisan will be readily recognize that the invention is not limited to these examples.

Examples

Example 1: Construction of Vectors

Production of the vector pTGFG1: The vector pUC19 (MBI Fermentas) was digested with XbaI, treated with Klenow enzyme and religated. This XbaI deleted vector was then digested with EcoRI, treated with Klenow enzyme and religated in order to delete the EcoRI site. For insertion of a XbaI site in the SacI site of this vector it was digested with SacI, treated with T4-polymerase, dephosphorylated with alkaline phosphatase and ligated with the XbaI-linker CTCTAGAG (Biolabs #1032). Another XbaI-site was inserted by digesting the newly produced vector with HindIII, treating it with Klenow, dephosphorylating it with alkaline phosphatase and ligating it with the XbaI-linker CTCTAGAG (Biolabs #1032). This vector was named pUC19/X.

In order to destroy the XbaI-site present in the vector pHGFP-S65T (Clontech) this vector was digested with XbaI, treated with Klenow enzyme and religated resulting in the vector pGFP/0. A 2.3 kb fragment containing the GFP-Gene was isolated after digesting pGFP/0 with MluI, treating it with Klenow enzyme and digesting it with BamHI. This fragment was inserted into the multiple cloning site of the vector pUC19/X which was digested with SalI, treated with Klenow enzyme and digested with BamHI. The resulting vector was named pTGFG1 (Figure 2).

Starting with this vector all the vectors described in Table 1 were obtained. At the restriction sites for PstI, KpnI, Ehel, EcoO109 and/or SapI a PRE(ds) was inserted giving rise to plasmids carrying the GFP gene and up to five PREs. By exchanging the GFP gene with a FIX gene a set of FIX expression plasmids were obtained. By excising the GFP gene the cloning vectors without a transgene were obtained.

Production of the insert PRE(ds): The oligonucleotides (Metabion) PRE-S (5'-GGG GTA CCA GCT TCG TAG CTA GAA CAT CAT GTT CTG GGA TAT CAG CTT CGT AGC TAG AAC ATC ATG TTC TGG TAC CCC-3'; SEQ ID NO: 3) and PRE-AS (5'-GGG GTA CCA GAA CAT GAT GTT CTA GCT ACG AAG CTG ATA TCC CAG AAC ATG ATG TTC TAG CTA CGA AGC TGG TAC CCC-3'; SEQ ID NO: 4) were hybridized and phosphorylated by kinase reaction, resulting in the insert PRE(ds).

Production of the vector pTGFG5: The vector pTGFG1 was digested with EcoO109I, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert,

resulting in the vector pTGFG5 (Figure 3), i.e., a vector which carries a PRE at position C of Fig. 2.

Production of the vector pTGFG20: The vector pTGFG1 was digested
5 with KpnI, treated with T4-polymerase and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in the vector pTGFG7. This vector pTGFG7 was digested with PstI, treated with T4-polymerase and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in
10 the vector pTGFG11. Subsequently, pTGFG11 was digested with EcoO109I, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It was then ligated with the PRE(ds) insert, resulting in the vector pTGFG20 (Figure 4). This vector carries a PRE at positions A, B and D of Fig. 2.

15

Production of the vector pTGFG33: In a similar manner PRE(ds) were inserted at the restriction sites for PstI, KpnI, EheI, EcoO109 and Sapi in vector pTGFG1 giving rise to the plasmid pTGFG33 (Figure 5), which is a vector that carries the GFP gene and five PREs, one each in
20 position A, B, C, D, E (Figure 2).

Production of the vectors pTGFG36, pTGFG53 and pTGFG64: The vector pUC19 (MBI Fermentas) was digested with SalI, treated with Klenow enzyme and dephosphorylated with alkaline phosphatase. It
25 was ligated to the NotI-linker GCGGCCGC (Biolabs # 1045), resulting in the vector pUC19/N.

A 1.4 kb fragment containing the open reading frame of the human clotting factor IX, isolated from a human cDNA library (see example 2), was inserted into the PstI-site of the vector pUC19/N
30 which was digested with PstI, treated with T4-polymerase and

dephosphorylated with alkaline phosphatase. From the resulting vector pUC19/N-FIX a 1.4 kb fragment containing the open reading frame of the human clotting factor IX was cut out by double-digestion with Hind III and NotI. This fragment was ligated to the 4.3 kb
 5 fragment of the HindIII and NotI double-digested vector pTGFG5 resulting in the vector pTGFG36 shown in Figure 6. This vector is a preferred one for delivery of Factor IX into the cell, and its DNA sequence is provided in Figure 9 (SEQ ID NO: 1).

In a similar manner plasmids pTGFG53 and pTGFG64 (shown in
 10 Figures 7 and 8) were obtained by exchanging the GFP gene in plasmids pTGFG20 and pTGFG33 by the FIX gene.

Production of the insert ALLG(ds): The oligonucleotides (Metabion)
 ALLG1/1 (5'-AGC TTG ACC TCG AGC AAG C-3') (SEQ. ID NO: 5) and
 ALLG2 (5'-GGC CGC TTG CTC GAG GTC A-3') (SEQ. ID NO: 6) were
 15 hybridized and phosphorylated by kinase reaction, resulting in the inserts ALLG(ds). The insert ALLG (ds) was constructed to introduce into the vector of choice a sequence with a multiple cloning site for the possible introduction of other transgenes.

Table 1 gives an overview of the available vectors with different
 20 transgenes and a different number of PREs in various positions. The positions of the PREs are given according to Figure 2. For the underlined vectors a map is provided (Figures 3 to 8).

Table 1: Vectors of the invention

Plasmid	Trans-gene	PRE	Plasmid	Trans-gene	PRE	Plasmid	Trans-gene	PRE
pTGFG0	--	--	pTGFG18	GFP	BDE	pTGFG34	FIX	E
<u>pTGFG1</u>	GFP	--	pTGFG19	GFP	BCD	pTGFG35	FIX	A
pTGFG2	FIX	--	<u>pTGFG20</u>	GFP	ABD	<u>pTGFG36</u>	FIX	D
pTGFG3	GFP	E	pTGFG21	GFP	CDE	pTGFG37	FIX	C

pTGFG4	GFP	A	pTGFG22	GFP	ACD	pTGFG38	FIX	B
<u>pTGFG5</u>	GFP	D	pTGFG23	GFP	ABC	<u>pTGFG53</u>	FIX	ABD
pTGFG6	GFP	C	pTGFG24	GFP	ABE	<u>pTGFG64</u>	FIX	ABCDE
pTGFG7	GFP	B	pTGFG25	GFP	ACE	pTGFG66	--	A
pTGFG8	GFP	BC	pTGFG26	GFP	ADE	pTGFG67	--	D
pTGFG9	GFP	BE	pTGFG27	GFP	BCE	pTGFG68	--	C
pTGFG10	GFP	BD	pTGFG28	GFP	BCDE	pTGFG69	--	B
pTGFG11	GFP	AB	pTGFG29	GFP	ACDE	pTGFG82	--	ABD
pTGFG13	GFP	CD	pTGFG30	GFP	ABCE	pTGFG95	--	ABCDE
pTGFG14	GFP	AC	pTGFG31	GFP	ABDE			
pTGFG15	GFP	DE	pTGFG32	GFP	ABCD			
pTGFG16	GFP	AD	<u>pTGFG33</u>	GFP	ABCDE			

For the DNA sequence of pTGFG 36, pTGFG 53, pTGFG 64, pTGFG 67, pTGFG 82 and pTGFG 95, see SEQ ID NOs: 1 and 13 to 17, respectively.

5

Example 2: Isolation of Human Factor IX cDNA

Factor IX cDNA was amplified from human liver cDNA (Clontech) using two primers overlapping the start and termination codon of the factor IX open reading frame resulting in a 1387 bp fragment containing the entire open reading frame. Restriction sites for EcoRI (upstream) and BamHI (downstream) were included at the end of each primer to facilitate cloning. Amplification was performed with Pwo polymerase (Boehringer Mannheim) in 50 ml reaction volume [10 mM Tris HCl pH 8.85, 25 mM KCl, 5 mM (NH₄)₂SO₄, 2 mM MgSO₄] with 30 incubation cycles at 96°C for 1 min, 60°C for 1 min, 72°C for 2 min, followed by a final extension step at 72°C for 10 min.

Reaction products were ligated into the EcoRI- and BamHI-sites of pUC19 and transformed into *E. coli* DH5-a. Positive clones were

selected. Sequences were confirmed by cycle sequencing (Amersham) from both ends with labeled primers (IR-700) and automated analysis on the LiCor sequencing system (MWG, Biotech).

The following primers were used :

- 5 GGAATTCGCAAAGGTTATGCAGCGCGTGAACATGATCATGGC
(upstream; SEQ. ID NO: 7)
CGCGGATCCATTAAGTGAGCTTTGTTTTTTCCTTAATCC (downstream;
SEQ. ID NO: 8)

10 **Example 3: Expression and Quantification of the Marker Protein GFP**

Method 1: HeLa cells were transfected by electroporation with plasmids pTGFG5 or pTGFG20. Transfected cells were harvested and
15 the cell pellets were homogenized and lysed in a buffer containing phosphate buffered saline (pH 7.5) and 10 mM PMSF. The concentration of green fluorescent protein (GFP) in the cell homogenate was determined by competitive ELISA.

For this purpose, GFP was coated in a defined concentration on
20 microtiter plates. Then, GFP samples were added in the presence of anti-GFP antibody. After several washing steps a labeled secondary antibody was added in order to trace the first antibody. The colorimetric reaction was measured photometrically (extinction). Generally, the more GFP was added the less antibody was left to bind
25 the coated GFP. Thus, reduction of extinction corresponded to higher GFP concentration in the sample.

A concentration curve of GFP was determined by linear regression (Figure 11) using bovine serum albumin (BSA) as a reference. A mean value of 2.4 mg GFP/ml for pTGFG5 (1 PRE) and
30 5.2 mg GFP/ml for pTGFG20 (3PREs) was found.

Figures 12 a-d show micrographs of HeLa cell cultures transfected with pTGFG5 (Fig. 12 a and b) and pTGFG20 (Fig. 12 c and d), respectively. Figures 12 a and c represent light microscopic views as controls, and Fig. 12 b and d show the corresponding cell patches in the fluorescent mode. Routinely, more than 50% of the cells expressed GFP, indicating very efficient transfection, the presence of only one PRE showing more efficient expression.

Method 2: 293 T cells were transfected with pTGFG 5, 20 and 33 using calcium phosphate method and fluorescence was detected with a fluorimeter (LabSystems, Extinction: 485 nm Emission: 520 nm). In the case of the mock transfection, non GFP-expressing DNA was used. Background indicates the fluorescence of the empty plate (96-well plate, Dynex, Immulon-4). The results are summarized in Fig. 13. Again the vector with just one PRE (pTGFG5) shows the highest expression.

Example 4: Human Factor IX Quantification by ELISA Assay

HeLa cells were transfected either by electroporation or using liposome reagent DOTAP (Boehringer Mannheim) with plasmids pTGFG36, pTGFG53 and pTGFG64. These plasmids contain the cDNA of human clotting factor IX. Recombinant human factor IX was secreted into the supernatant of the cell culture and quantified using a sandwich ELISA method.

0.11 M sodium citrate and 10 mM PMSF were added in order to prevent degradation of human factor IX. The enzyme-immunological in vitro assay "Asserachrom IX:AG" from Boehringer-Mannheim was used in order to determine the concentration of expressed human

clotting factor IX. The factor IX-standard from Octapharma AG was used as a standard in aqueous solutions of 28 IU/ml.

In six different transfection experiments, in which HeLa cells with plasmids containing human factor IX-cDNA (pTGFG36, 53 and 64) were transfected using either electroporation or lipid-transfection reagent (DOTAP, Boehringer Mannheim), a concentration range of 3-25 ng/ml human clotting factor IX was reached.

Example 5: Production and Purification of hPR (A Form)

10

1. Cloning of the human progesterone receptor: The cloning was performed as follows: Total human RNA was isolated from human white blood cells or liver cells using cell lysis in guanidinium hydrochloride buffer and CsCl-density centrifugation.

15 For cloning of the hPR coding sequence, hPR specific cDNA was prepared and used for amplification of the hPR coding sequence in two fragments by PCR.

The following oligonucleotide primers were selected based on the published mRNA sequence (Genbank: NM_000926 and X51730).

20 Oligonucleotides used were obtained from MWG, Ebersberg or Metabion, München. All primers used are listed 5' to 3', bases added to introduce restriction sites are in capital letters and restriction sites used for cloning are underlined.

hPGR-5'-primer: CGA GGA tcc agt cgt cat gac tga gc (SEQ ID NO: 9);

25 hPGR-3'-primer: GCA GAA TT cat tat aaa aac tca aga cct cat aat cct gac (SEQ ID NO: 10);

hPGR-internal primer (Sal I) 1: ctc ctc ggg gtc gac cct gg (SEQ ID NO: 11);

30 hPGR-internal primer (Sal I) 2: cca ggg tcg acc ccg agg ag (SEQ ID NO: 12).

Synthesis of cDNA was performed using 3 µg of total RNA and 200 pmol of the 3'-primer with SuperScript II reverse transcriptase (Gibco BRL). Reaction volume was 50 µl and buffer was used as recommended, supplemented with RNase Inhibitor and 10 mM DTT and 1 mM dNTPs. Before adding the enzyme, samples were heated to 80°C for 10 min, followed by 10 min at 72°C and 10 min at 42°C. SuperScript II RT was added at 42°C and reaction was continued for 15 min at 42°C, 15 min at 50°C and 1 h at 58°C.

10

The cDNA obtained from this synthesis reaction was used to amplify the hPGR coding sequence in two fragments by PCR. One fragment (5') with 5'-primer and internal primer 2 and one fragment (3') with 3' primer and internal primer 1. Reaction setup in 50 µl was : Two polymerase (Roche Diagnostics), buffer as supplied by Roche Diagnostics, supplemented with DMSO, 50 pmol of each primer and 0.2 mM dNTPs. Reaction conditions were: 10 min 96°C followed by 35 cycles of 1 min 96°C, 2 min at 59°C, 2 min 72°C and a final extension step at 72°C for 10 min.

20

PCR-products were purified by gel electrophoresis and digested with Sal I. The BamHI and Hind III sites introduced in the primer were not used to avoid cutting at two internal restriction sites of the hPR coding sequence. Both fragments were ligated into pBluescript SK+ vector cut with EcoRV through blunt end ligation into the vector and sticky end ligation through the internal Sal I site. Vectors containing the appropriate insert were identified by mini-prep, restriction digest and sequencing. The obtained vector was designated pTGhPR1.

25

2. Production of hPR (A-form): Initially, the gene for hPR-B inclusive its 3'-UTR was cut out from pTGh PR1 and cloned in frame in the multiple cloning site of the expression plasmid pFASTBAC HTc (BAC-to-BAC Baculovirus Expression System, Life Technologies). This
 5 resulted in an expression cassette of a N-terminally histidine-tagged version of hPR-B under expression control of the viral polyhedrin promotor as shown below. A rTEV protease cleavage site is located between the six histidine residues and the initial methionine of the hPR-B reading frame, which allows removal of the histidine residues
 10 from the expressed protein. The N-terminal region of the expression cassettes is shown below.

MSYYHHHHHHHDYDIPTTENLYFQ**GAMGIRNST-hPR-gen
 6 x His _____
 15 spacer _____
 rTEV cleavage site

Amino acids are presented in the single letter code. The cleavage site of the rTEV protease is represented by **

20 In order to generate the expression cassette for the truncated hPR-A form, the DNA sequence encoding for the amino acids between Met 1 and Met 165 of the hPR-B form was removed using a PCR-based strategy. Two primer pairs were designed which allowed amplification
 25 of either a DNA fragment just downstream of the start AUG of the hPR-B gene and a DNA-fragment just upstream of the AUG coding for Met 165, respectively. In a subsequent PCR reaction these two DNA fragments were annealed to each other at their homologous 3'-ends, and amplified using the outermost amplification primers. The resulting
 30 DNA-fragment was digested by EcoRI and Mlu I and the cleavage product was exchanged against the corresponding fragment of the

hPR-B expression cassette in the pFASTBAC HTc vector. Thereby the reading frame coding for an N-terminal histidine tagged version of the hPR-A polypeptide (94kDA) was restored.

This 6×His-tag was utilised for affinity purification of the protein
5 by immobilized cobalt²⁺ affinity chromatography on a TALON® resin (Clontech). The procedure, following the method of Boonyaratanakornkit et al. Mol. Cell. Biol. 18, 4471 (1998), was as follows (all steps were carried out at 0 to 8°C):

Sf9 cells were cultivated in monolayer culture in serum free SF900
10 medium. Viral infection of the cells was done at a multiplicity of infection (MOI) of 5-8.

The harvesting was done 48 hours after infection with baculovirus containing the hPR expression cassette and lysed mechanically by homogenising in buffer A containing 20 mM Tris-Cl pH 8.0, 350 mM
15 NaCl, 10 mM imidazol, 5% glycerol and a cocktail of proteinase inhibitors (Complete™ EDTA-free, Roche Diagnostics, Penzberg, Germany). After a 10 min centrifugation at 10000 x g, supernatant originating from 10⁸ cells was incubated for 1 h with 0,5 ml settled TALON® resin equilibrated in buffer A. TALON® was washed with 20
20 volumes of buffer A. hPR-A was eluted with 10 Vol buffer B, containing all ingredients of buffer A, but 100 mM imidazol. The eluate was concentrated 50-fold and dialysed against 100 volumes buffer C (PBS + 100 nM progesteron) by centrifugal ultrafiltration at a molecular exclusion size of 10 kDa (Centricon Plus-20 PL-10, Millipore, Eschborn,
25 Germany).

3. Determination of identity, purity and yield of hPR-A: Purity and yield of the product were determined by application on denaturing reducing polyacrylamid- gelelectrophoresis according to Laemmli, U.
30 et al., Nature 227, 680-685 (1970) and subsequent staining with

coomassie® blue R250. By this one-step procedure hPR-A was enriched to a final specific hPR content of 0.2 - 0.5 mg hPR/mg protein. As depicted in Figure 15, lane A, the final preparation consisted predominantly of two distinct protein species displaying
5 apparent molecular masses of 94 and 74 kDa (Fig. 15, arrows).

Yield was estimated by parallel separation of standardised protein preparations. Data taken from a set of three separate experiments hint at a typical yield of 30 µg enriched hPR A-receptor per 10⁸ cells.

10 Identity of hPR was determined by immunodetection of the product transferred to nitrocellulose by western blotting with mouse monoclonal antibodies directed against recombinant hPR (PR Ab-1, Oncogene, Cambridge, MA, USA).

The final product was transferred to nitrocellulose BA-83 and
15 immunostained as described above. As presented in Figure 15, lane C, three major protein bands were detected, including the two dominant protein species described above. The smaller sized bands may display copurified proteolytic fragments of hPR.

Intracellular GFP from adherent cells was detected by a
20 fluorimeter after media was taken off and PBS (colourless) was added. The results are summarized in Fig. 13.

Example 6: Clotting Activity of Human Clotting Factor IX from Transfected 293 T Cells

25

A concentration range of 55 - 95 ng/ml human clotting factor IX has been reached by transfection of 293 T-cells with plasmids containing human factor IX-cDNA (pTGFG 36, 53, 64 and 2) in 11 different experiments using ELISA (Example 4).

30

Clotting activity was determined with a partial thromboplastin time

assay using Cephalin (phosphatidyl ethanolamine) activation with a manual coagulation instrument (ML-2, Instrumentation Laboratories). For the study, 100 µl undiluted supernatant from transfected 293 T-cells, 100 µl deficiency plasma (Progen) and 100 µl Cephalin (Instrumentation Laboratories) were incubated for 5 minutes at 37°C. Coagulation was started by adding 100 µl CaCl₂. Sample coagulation time was compared to normal plasma.

Number of cells [/ml]	Factor IX-concentration [ng/ml]	Clotting time [s]
2,1 x 10 ⁵	36	45
8,7 x 10 ⁵	20	79

10 Normal plasma: 37 – 39 s
Factor IX deficient plasma: 137 – 140 s

Example 7: Analysis of an Additive Effect of Human Clotting Factor IX on the Clotting Time of Mice Blood

15

1. Clotting time: Clotting activity was determined with a partial thromboplastin time assay using Cephalin (phosphatidyl ethanolamine) activation with a manual coagulation instrument (KC 4 A, Amelung).

20 For the study, 5 µl mouse blood, 20 µl deficiency plasma (Progen) and 100 µl physiological NaCl and 100 µl DaPPTin (Progen) were incubated for 2 minutes at 37°C. Coagulation was started by adding 100 µl CaCl₂.

To analyse the additive effect, human clotting factor IX (housestandard, Octapharma) was added to the mouse blood and diluted 1:10 within the system. As it is shown in Figure 15, the additive effect of human clotting factor IX on clotting activity can be

25

detected up to a limit concentration of 0,07 mIU hFIX/ml (= 31,5 ng/ml).

55 2. ELISA: The addition of human clotting factor IX to the mouse blood was monitored by ELISA as described in Example 4. Citrate plasma was made out of mouse blood and human clotting factor IX was added in different concentrations.

No.	Description	Concentration [mIU/ml] hFIX added	Extinction at 405 nm [-]
1.	Mouse Citrate Plasma	7	0,204
2.	Mouse Citrate Plasma	2	0,130
3.	Mouse Citrate Plasma	-	0,099
4.	Control: 1.+2. Antibody without antigen	-	0,096
5.	Control: 1. Antibody without antigen	-	0,072
6.	Control: 2. Antibody without antigen	-	0,085
7.	Substrate (ABTS)	-	0,072

10 Mouse plasma without the addition of human clotting factor IX showed an extinction of 0,099 at 405 nm background. When added human factor IX in a concentration of 2 mIU/ml (= 9 ng/ml human factor IX) the detection limit is reached. It can be deduced that the antihuman factor IX antibodies used in the ELISA are not cross-reactive with
15 mouse coagulation factor IX.

Example 8: Cloning and Activity Testing of the Human Progesterone Receptor (hPR)

2. Activity Testing: The human progesterone receptor encoded in
- 5 plasmid pTGhPR1 (s. Example 8.1 above) was tested for its physiological activity. In a functional form and after activation with a progestin like R5020 the receptor should be able to induce the expression of luciferase from a Mouse Mammary Tumor Virus (MTV) promoter.
- 10 To test this 293T cells were grown in phenol red-free DMEM supplemented with 10% charcoal-filtrated fetal calf serum and with or without 10 nM of R5020 (NEN) in 6 well plates. Transfections were performed by the calcium phosphate method using 2 µg of a pSG-hPR1 constructt and pMTV-luc (Hollenberg et al., 1985, Cell 55, p899-
- 15 906) per well. One day after transfection the cells were washed in PBS and the luciferase expression assayed with the Berthold luciferase kit according to the manufacturer's directions in a fluorimeter (Labsystems). The controls were as follows: R5020 was omitted (PR+MTV) and both plasmids alone were transfected with (PR+R5020,
- 20 MTV+R5020) and without R5020 (PR, MTV). As positive control a plasmid with a CMV-driven luciferase gene was transfected (pCMV-luc).

As can be seen in Figure 19, there is a clear induction of luciferase expression when all the necessary elements are present,

25 that is human progesterone receptor, progestin R5020 and the MTV-driven luciferase gene (PR+MTV+R5020). The error bars give the standard deviation of a threefold experiment, the readout is relative light units (RLU).

Example 9: Oral Gene Transfer in *in vivo* Animal Experiment

Purpose of experiment: The object of this pilot study is to prove oral gene transfer in an *in vivo* animal experiment. Successful gene transfer is established by coagulation measurement: an additive effect of expressed human factor IX on the coagulation time of healthy murine whole blood is expected. The presence of expression of human factor IX in mouse blood is quantitated by ELISA.

Animals: The animals employed are 35 male C57BL/6J mice from Iffa Credo, France, with an initial age of 9 weeks and a weight of 23-33 g. The mice are kept in groups of 7 animals each in conventional test animal cages with wooden chips in the Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München.

The animals are fed ad libitum with "Altrum Ratten und Mäuse Haltung" and are given tap water, also ad libitum.

The test animal cages are kept at an ambient temperature of 19-24°C and a humidity of 55-55%. The room is additionally provided with an automatic light supply which maintains a 12 hours rhythm.

The test animals are supervised by specialized staff.

Mixture of substances:

Group	Hormone	Hormone receptor	Plasmid	Aqua dest.	Route of administration
1. -	-	-	-	-	-
2. -	100 µl	-	10 µg	-	oral
3. -	-	-	10 µg	100 µl	oral
4. -	-	-	10 µg	50 µl	i.m.
5. -	100 µl	4.35 µg	10 µg	-	oral

Plasmid and hPR: Theragene GmbH

Hormone: Utrogest® by Dr. Kade/Besins Pharma GmbH,
Rigistr. 2, D-12277 Berlin

Aqua dest.: Aqua ad injectabilia Delta-Pharma GmbH, 72793
Pfullingen

Esophageal sound: Vein catheter, diam. 0.5 x 0.9 mm,
Lot 7077 G2221, B. Braun Melsungen AG, Western
Germany

i.m. injection: Micro-Fine 12.7 mm, Becton Dickinson GmbH,
Tullastr. 8-12, D-69126 Heidelberg

Course of experiment: The 35 mice were divided into 5 groups of 7 mice each. One group serves as a control, the second group was daily administered a total of 100 µl of hormone and plasmid via the gastrointestinal tract orally with an esophageal sound, the third group was daily administered a total of 100 µl of plasmid with aqua dest. orally with an esophageal sound, the fourth group was administered a total of 50 µl of plasmid with aqua dest. i.m. into the musculus quadriceps femoris, the fifth group was daily administered a total of 100 µl of hormone, hormone receptor and plasmid orally with an esophageal sound.

About 2-3 hours before the manipulation, the mice were prewarmed under a red light. Immediately before, during and after the manipulation, the mice were examined and supervised by a veterinarian.

Blood sampling from the mice was performed daily from the caudal artery of animals slightly sedated by inhalation anesthesia. For this purpose the artery was punctured with a disposable injection cannula (0.90 x 40 mm). Whole blood welling out of the puncture site (5 µl of blood) was immediately collected with an Eppendorf pipette.

Without further delay, the blood coagulation time in seconds was

determined using an Amelung-Koagulometer KC 4A by means of an aPTT assay (activated partial thromboplastin time). The blood coagulation analysis was always performed by the same person. Immediately after the blood sampling, the bleeding was stopped by
5 compression.

Sedation of the mice was achieved by inhalation anesthesia (active substance: isoflurane: Forene, Abbott GmbH, 65205 Wiesbaden, Western Germany) in a whole body chamber.

The daily manipulation was performed through an overall period of 7
10 days. This was followed by a day (day 8 of experiment) without any manipulation, and at day 9 of experiment, again 5 µl of whole blood was withdrawn from the ventral caudal artery under anesthesia, and the coagulation time established as described above. Further, 0.5-0.75 ml of whole blood was collected intracardially using U-40 insulin
15 syringes (Mikro-Fine 12.4 mm) filled with 50-75 µl of sodium citrate (3.1%), transferred into Eppendorf cuvettes, and about 100 µl of whole blood with citrate was reserved for PCR examination and stored in a cool environment. The remaining citrate blood was centrifuged for 10 min using a centrifuge 6000 rpm, 4°C, at 5000 rpm, and the plasma
20 was recovered for the ELISA determination of the factor IX concentration.

Then, the animals were sacrificed using 0.5 ml Narkoren i.p. Immediately after the sacrificing, the animal bodies were dissected. The following organs were removed from the mice for an
25 immunohistochemical examination: brain, spleen, liver, kidneys, testes, lungs, m. quadriceps femoris, heart, appendix; and frozen at -80°C.

Deviation from the scheduled experimental course: Due to the poor general condition of the mice in the course of the long-term
30 administration series, the administration had to be interrupted at days

3 (except one mouse) and 5 for test group 2 (hormone and plasmid), at days 3 and 5 for group 5 (hormone, hormone receptor and plasmid), and two mice were additionally spared the administration of the reagents at days 2 and 7 of the experiment.

5 The poor general condition is accounted for by the hypnotic effect of the hormone progesterone. It causes the mice to sleep for about 24 hours without eating and drinking. This again has an adverse effect on the water balance of the mice, resulting in exsiccotic phenomena and apathic behavior. Therefore, the mice were prophylactically treated with
10 a subcutaneous administration of 1 ml of 5% glucose solution (Delta Pharma GmbH, 72793 Pfullingen) and 1 ml of Ringer solution (Delta Pharma GmbH, 72793 Pfullingen) when the hormone was administered orally. Among the group which was orally administered hormone, hormone receptor and plasmid, two mice died at days 3 and 6,
15 respectively; they were dissected.

 Among the group which was orally administered hormone with plasmid, one mouse was found dead in its cage on day 8 of the experiment; it was also dissected.

 The results are summarized in Figures 17 and 18. The statistical
20 evaluations were performed according to the generalized linear model with repeated measurements (MANOVA with repeated measurements). In none of the test groups a non-linear course was observed. Therefore, the course was calculated by a simple representation of the linear increase or decrease, namely initial value minus final value per
25 mouse. The particularly interesting difference between the control and the group "plasmid in the hormone with hormone receptor" (group 5) was examined using a T test for Independent random samples.

 Figure 17 shows the mean values of the calculated differences: In the control, for example, this difference was about 50 seconds. The
30 vertical lines show plus and minus one standard deviation from these

values. The T test is based both on the differences between the mean values and on the degree of overlapping which can be seen from these lines: The larger the overlapping, the less is the significance of the mean value differences. Thus, the groups "control" and "plasmid and water i.m." (groups 1 and 5, respectively) are distinguished in a purely numerical way in the mean value, but the degree of overlapping is so high that these groups are not significantly different.

The only significant difference was between group 1 and 5: The decrease of the latter is significantly higher than that of the control ($T = -2.357$; d.f. = 12; $p < 0.05$).

The following Tables contain the concluding statistics and the results of the statistical tests (T test) performed on the differences between the mean values obtained in the course of the test:

15

Group statistics

ADMIN		N	mean value	standard deviation	standard error of the mean value
DIF	control	7	47.3857	58.9946	22.2978
	Hormone, hormone receptor and plasmid orally	7	114.7571	47.3300	17.8891

Test for independent random samples

		Levene test for equal variance		T test for equal mean values						
		F	Significance	T	df	sig. (2-sided)	mean difference	standard error of difference	95% confidence interval of difference	
									lower	upper
DIF	variances are equal	0.026	0.874	-2.357	12	0.036	-67.3714	28.5869	-129.6570	-5.0858
	Variances are not equal			-2.357	11.461	0.037	-67.3714	28.5869	-129.9833	-4.7596

The human F IX was also detectable in the treated mice of the "hormone-hormone reception and plasmid orally group using an Elisa
 s as described in Example 4.

Claims

1. Use of a nucleic acid construct comprising at least one hormone responsive element (HRE) and a transgene for preparing an agent for
5 gene transfer.
2. The use of claim 1, wherein the at least one HRE is functionally linked to the transgene or not.
- 10 3. The use of claim 1 or 2, wherein the transgene is selected from the group consisting of genes encoding a blood clotting factor, hormone genes, hormone receptor genes, growth factors, enzyme genes, genes encoding cytokines or lymphokines, genes encoding inhibitor substances, genes encoding substances that function as drugs or
15 vaccines, and antisense sequences.
4. The use of claim 3, wherein the transgene is a gene encoding a blood clotting factor and the agent is suitable for treating hemophilia.
- 20 5. The use of claim 4, wherein the human blood clotting factor is selected from the group consisting of factor VIII, factor IX, and von Willebrand Factor (vWF).
6. The use of claims 1 to 5, wherein the nucleic acid construct
25 comprises 1 to 20, preferably 3 to 10 HRE(s).
7. The use of claim 1 to 5, wherein the at least one HRE is a steroid responsive element, preferably a progesterone responsive element (PRE).

8. The use of claim 5, wherein the HRE is a PRE and the blood clotting factor is factor IX, preferably the factor IX has a nucleotide sequence of 689 to 2071 of SEQ ID NO: 1.
- 5 9. The use of claim 5, wherein the HRE is a PRE and the blood clotting factor is factor VIII.
- 10 10. The use of claim 7 to 9, wherein the PRE has the double stranded DNA sequence comprised of the DNA sequences of SEQ ID NOs: 3 and 4.
- 15 11. The use of claims 1 to 10, wherein the construct further comprises functional DNA sequences selected from the group consisting of promoter sequences, enhancer sequences, silencer sequences, origin of replication sequences, integrational sequences, marker genes and switch sequences.
- 20 12. The use of claim 11, wherein the construct further comprises a tissue-specific promoter, preferably an α -antitrypsin promoter.
13. The use according to any one of claims 1 to 12, wherein the agent further comprises a hormone-hormone receptor complex, preferably a steroid-steroid receptor complex.
- 25 14. The use of claim 13, wherein the molar ratio of HRE within the nucleic acid construct to hormone receptor is from 1:1 to 1:10, preferably 1:2 to 1:5, and/or the molar ratio of hormone to hormone receptor is at least 1000:1, preferably at least 10000:1.
- 30 15. The use of claim 13 or 14, wherein the receptor is a progesterone

receptor and the steroid is progesterone or a progesterone derivative.

16. The use of claim 15, wherein the progesterone is natural
micronized progesterone solubilized in a lipophilic matrix system
5 and/or the progesterone receptor is hPR-A, hPR-B or comprises the
nucleotide sequence of 557 to 933 SEQ ID NO: 9.

17. A nucleic acid construct comprising at least one HRE and a
transgene, wherein one of said at least one HREs is not functionally
10 linked to the transgene.

18. The nucleic acid construct of claim 17, which is as defined in
claims 3 to 12.

15 19. A vector comprising the nucleic acid construct of claim 17 or 18.

20. A transformed cell or transgenic organism comprising the nucleic
acid construct as defined in claims 17 or 18 or the vector as defined in
claim 19.

20

21. A composition of matter comprising a nucleic acid construct
comprising at least one HRE and a transgene as defined in claim 17 or
18 and/or a vector as defined in claim 19, said at least one HRE being
coupled to a hormone-hormone receptor complex.

25

22. The composition of matter of claim 21, wherein the hormone-
hormone receptor complex is as defined in claims 13 to 16.

23. The composition of matter of claim 21, wherein the transgene is a
30 gene encoding a blood clotting factor.

24. The composition of matter of claim 21 wherein the blood clotting factor is factor IX.

5 25. The composition of matter of claim 21 wherein the blood clotting factor is factor VIII.

26. A method for preparing the composition of matter as defined in claim 21, which method comprises admixing the nucleic acid construct
10 with the hormone receptor and the hormone.

27. A pharmaceutical composition comprising the nucleic acid construct of claim 17 or 18, the vector of claim 19, and/or the composition of matter of claim 21 to 25.

15

28. The pharmaceutical composition of claim 27, which is suitable for gene transfer, preferably for treating hemophilia.

29. A method for gene transfer which comprises administering the
20 agent as defined in claims 1 to 16, or the composition of matter as defined in claims 21 to 25 to an organism or to a cellular system.

30. A method for delivering into an organism or into a cellular system a nucleic acid encoding a transgene to be expressed in the cells of the
25 organism or the cells of the cellular system, which method comprises administering an agent as defined in claims 1 to 16 or composition of matter as defined in claims 21 to 25 to the organism or to the cellular system so that the hormone in the composition interacts with the cell membrane and therewith enhances diffusion and transport of the

nucleic acid that is coupled to the hormone-hormone receptor complex across the membrane and into the cell.

31. The method of claim 30, wherein a nucleic acid encoding human
5 factor VIII or factor IX is delivered into the cell.

32. A method of treating blood clotting disorders comprising
administering a therapeutically effective amount of the composition of
matter of claim 23 to an organism or to a cellular system.

10

33. A method of treating hemophilia B, comprising administering a
therapeutically effective amount of the composition of matter of claim
24 to an organism or to a cellular system.

15 34. A method of treating hemophilia A, comprising administering a
therapeutically effective amount of the composition of matter of claim
25 to an organism or to a cellular system.

35. Use of a steroid hormone for preparing an agent for gene transfer.

20


36. The use of claim 35, wherein the steroid hormone is a natural
micronized steroid hormone, preferably natural micronized
progesterone.

25 37. The use of claim 36, wherein the natural micronized steroid
hormone is solubilized in a lipophilic matrix system.

38. A method for gene transfer which comprises administering a
nucleic acid construct to an organism or to a cellular system, wherein


the nucleic acid construct contains a transgene and is encapsulated in a steroid hormone.

Fig. 1




2/22

Fig. 2




3/22

Fig. 3




4/22

Fig. 4




5/22

Fig. 5




6/22

Fig. 6




7/22

Fig. 7



8/22

Fig. 8



9/22
Fig. 9

CGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTTC
CGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAG
TACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAG
TACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTG
GCAGTACATCAATGGGCGTGGATAGCGTTTGACTCACGGGGATTTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTT
TGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGT
GTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCTGCTTACTGGCTTATCGAAATTAATAC
GACTCACTATAGGGAGACCCAAGCTTGCATGCCAATCCGCAAGGTTATGCAGCGCGTGAACATGATCATGGCAGAATC
ACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGTGAATGTACAGTTTTTCTTGATCATGAAAACGCCA
ACAAAATTTCTGAATCGGCCAAAGAGGTATAATTCAGGTAATTTGGAAGAGTTTGTTCAGGGAACCTTGAGAGAGAATGT
ATGGAAGAAAAGTGTAGTTTTGAAGAAGCAGAGAAGTTTTGAAAACACTGAAAGAACAACCTGAATTTTGAAGCAGTA
TGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTT
GGTGTCCCTTTGGATTGGAAGGAAGAAGCTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGATGCGAGCAGTTT
TGTAATAATAGTGTGATAACAAGGTGGTTGCTCCTGTACTGAGGGATATCGACTTGCAGAAAACCAAGTCTGTGA
ACCAGCAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTTCAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTCTCTG
ATGTGGACTATGTAATTTCTACTGAAGCTGAAACCATTTTGATAACATCACTCAAAGCACCAATCATTAAATGACTTC
ACTCGGGTTGTTGGTGGAGAGATGCCAAACCAGGTCAATTCCTTGGCAGGTGTTTTGATGGTAAAGTTGATGCATT
CTGTGGAGGCTCTATCGTTAATGAAAATGGATTGTAAGTCTGCCACTGTGTTGAACTGGTGTAAATTTACAGTTG
TCGCAGGTGAACATAATATTGAGGAGACAGAACATACAGCAAAAGCGAAATGTGATTGCAATTTATCTCCACCAAC
TACAATGCAGCTATTAATAAGTACAACCATGACTTGCCTTCTGGAAGTGGACGAACCTTAGTGCTAAACAGCTACGT
TACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAA
GAGTCTTCCACAAAGGGAGATCAGCTTTAGTTCTTCACTACCTTAGAGTTCCACTTGTGACCGAGCCACATGTCTTGA
TCTACAAAGTTTACCATCTATAACAACATGTTCTGTGCTGGCTCCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAG
TGGGGGACCCCATGTTACTGAAAGTGGAGGGACCAAGTTTCTTAAGTGGAAATATTAGCTGGGGTGAAGAGTGTGCAATGA
AAGGCAAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAAGGAAAAACAAAGCTCACTTAATGGGAT
CGGTGAGCGGCGCGACTCTACTAGAGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAACTA
CCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAACTACTGATTCTAATTTGTTG
TGTATTTTAGATTCCAACCTATGGAAGTGTGATGAGGAGCAGTGGTGGAAATGCCTTTAATGAGGAAAACCTGTTTGTCT
CAGAAGAAATGCCATCTAGTGTGATGAGGCTACTGTGACTCTCAACATTCTACTCTCCAAAAGAGAGAAAGGTA
GAAGACCCCAAGGACTTTCTTCCAGAAATGCTAAGTTTTTTGAGTCATGCTGTGTTAGTAATAGAAGCTTTGCTTGCTT
TGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAATATTGAAAAATATTCTGTAACTTTTATAAGTA
GGCATAACAGTTATAATCATAACATACTGTTTTTCTTACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCT
CAAAAATTTGTGTACCTTTAGCTTTTTAATTTGTAAGGGGTTAATAAGGAATATTGATGTATAGTGCCTTACTAGAGA
TCATAATCAGCCATACCATTGTTAGAGGTTTTACTTGCTTTAAAAAACCTCCACACCTCCCTGAACTGAAACAT
AAAATGAATGCCAATTGTTGTTGTTAACTTGTATTGTCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTT
CACAAATAAAGCATTTTTTCTACTGCATTCTAGTTGTGGTTTTGTCAAAACCTCATCAATGTATCTTATCATGTCTGGATCC
CCGGGTACCCTCTAGAGCGAATTAATTCAGTGGCCGTGTTTTTACAACGTCGTGACTGGGAAAACCTTGGCGTTACCCAA
CTTAATCGCCTTGACGACATCCCTTTTCGCGAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCTTCCCAACA
GTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGATTTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATAT
GGTGCACTCTCAGTACAATCTGCTCTGATGCCGATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCC
TGACGGGCTTGTCTGCTCCCGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCT
ACCGTCTACCCGAACGCGCGAGACGAAAGGGGGGTACCAGCTTCGTAGCTAGAACATCATGTTCTGGGATATCAGCT
TCGTAGCTAGAACATCATGTTCTGGTACCCCTCGTGAATACGCTATTTTATAGGTTAATGTCTAGATAATAAGGTT
TCTTAGACGTCAGGTGGCACTTTTCGGGAAATGTGCGCGGAACCCCTATTTGTTATTTTTCTAAATACATTCAATAT
GTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTTCC
GTGTGCGCCTTATTCCTTTTTGCGGCATTTTGCCTTCTGTTTTGCTCACCGAGAACGCTGGTGAAAGTAAAGAT
GCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCC
CGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACCGCGGCAAG
AGCAACTCGGTGCGCGCATACATACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCACTGCTGCCATAACCATGAGTGATAACACTGCGGCCAATTTACTTCTGACAACGAT
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGACAACATGGGGGATCATGTAACCTCGCTTGATCGTTGGGAACCGGAGC
TGAATGAAGCCATACCAACGACGAGCGGTGACACCCAGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAT
GGCGAACTACTTACTCTAGCTTCCCGGCAACAATAATAGACTGGATGGAGGCGGATAAAGTTGACGAGACCACTTCTGCG
CTCGGCCCTTCCGGCTGGCTGGTTTTATTGCTGATTAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCAC
TGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAGA
CAGATCGCTGAGATAGGTGCTCACTGATTAAAGCATTGGTAACTGTACAGACCAAGTTTACTCATATATACTTTAGATTGA
TTTTAAACTTCATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAAACGTG
AGTTTTCTGTTCCACTGAGCGTCAGACCCGTCAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATC
TGCTGCTTGCAAAACAAAAAACCCGCTACCAGCGGTGGTTTTGTTTGGCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACCTGGCTTCAGCAGAGCGCAGATACCAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCCTTCAAGAACT
CTGTAGCACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCTGTCTTACC
GGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTT
GGAGCGAACGACCTACACCGAAGTACAGCTGAGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAAG

10/22

Fig. 9 (continued)

CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTT
TATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAA
AAACGCCAGCAACCGCGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTGCTCACATGTTCTTTCCTGCGTTATCCC
CTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAG
TCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAATTAATGCAGCTG
GCACGACAGGTTTCCCGACTGGAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCC
AGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTAT
GACCATGATTACGCCAAGCTCTCTAGAGCTCTAGAGCTCTAGAGCTCTAGAGAGCTTGCATGCCTGCAGGTCG


11/22
Fig. 10

Met Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr
 1 5 10 15
 Ile Cys Leu Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr Val Phe Leu
 20 25 30
 Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn
 35 40 45
 Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu Cys
 50 55 60
 Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe Glu Asn
 65 70 75 80
 Thr Glu Arg Thr Thr Glu Phe Trp Lys Gln Tyr Val Asp Gly Asp Gln
 85 90 95
 Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly Ser Cys Lys Asp Asp Ile
 100 105 110
 Asn Ser Tyr Glu Cys Trp Cys Pro Phe Gly Phe Glu Gly Lys Asn Cys
 115 120 125
 Glu Leu Asp Val Thr Cys Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe
 130 135 140
 Cys Lys Asn Ser Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly
 145 150 155 160
 Tyr Arg Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala Val Pro Phe
 165 170 175
 Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu Thr Arg Ala
 180 185 190
 Glu Thr Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu Ala Glu
 195 200 205
 Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser Phe Asn Asp Phe
 210 215 220
 Thr Arg Val Val Gly Gly Glu Asp Ala Lys Pro Gly Gln Phe Pro Trp
 225 230 235 240
 Gln Val Val Leu Asn Gly Lys Val Asp Ala Phe Cys Gly Gly Ser Ile
 245 250 255
 Val Asn Glu Lys Trp Ile Val Thr Ala Ala His Cys Val Glu Thr Gly
 260 265 270
 Val Lys Ile Thr Val Val Ala Gly Glu His Asn Ile Glu Glu Thr Glu
 275 280 285
 His Thr Glu Gln Lys Arg Asn Val Ile Arg Ile Ile Pro His His Asn
 290 295 300

12/22

Fig. 10 (continued)

Tyr	Asn	Ala	Ala	Ile	Asn	Lys	Tyr	Asn	His	Asp	Ile	Ala	Leu	Leu	Glu	305	310	315	320
Leu	Asp	Glu	Pro	Leu	Val	Leu	Asn	Ser	Tyr	Val	Thr	Pro	Ile	Cys	Ile	325	330	335	
Ala	Asp	Lys	Glu	Tyr	Thr	Asn	Ile	Phe	Leu	Lys	Phe	Gly	Ser	Gly	Tyr	340	345	350	
Val	Ser	Gly	Trp	Gly	Arg	Val	Phe	His	Lys	Gly	Arg	Ser	Ala	Leu	Val	355	360	365	
Leu	Gln	Tyr	Leu	Arg	Val	Pro	Leu	Val	Asp	Arg	Ala	Thr	Cys	Leu	Arg	370	375	380	
Ser	Thr	Lys	Phe	Thr	Ile	Tyr	Asn	Asn	Met	Phe	Cys	Ala	Gly	Phe	His	385	390	395	400
Glu	Gly	Gly	Arg	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	His	Val	405	410	415	
Thr	Glu	Val	Glu	Gly	Thr	Ser	Phe	Leu	Thr	Gly	Ile	Ile	Ser	Trp	Gly	420	425	430	
Glu	Glu	Cys	Ala	Met	Lys	Gly	Lys	Tyr	Gly	Ile	Tyr	Thr	Lys	Val	Ser	435	440	445	
Arg	Tyr	Val	Asn	Trp	Ile	Lys	Glu	Lys	Thr	Lys	Leu	Thr				450	455	460	

13/22
Fig. 11




Fig. 12a




Fig 12 b



Fig 12 c




Fig 12 d



16/22
Fig. 13

Fig. 14



17/22

Fig. 15.





Fig. 16



19/22




Fig. 17





Fig. 18

20/22

Fig. 19



21/22

```
1  MTELKAKGPR APHVAGGPPS PEVGSPLLCR PAAGPFGSQ TSDTLPEVSA IPISLDGLLF
61 PRPCQGQDPS DEKTQDQQL SDVEGAYSRA EATRGAGGSS SSPPEKDSGL LDSVLDTLA
121 PSGPGSQPS PPACEVTSSW CLFGPELPED PPAAPATQRV LSPLMSRSGC K'GDSSGTAA
181 AHKVLPRGLS PARQLLLPAS ESPHWSGAPV KPSPQAAAVE VEEEDGSESE ESAGPLLKKG
241 PRALGGAAAG GGAAAVPPGA AAGGVALVPK EDSRFSAPRV ALVEQDAPMA FGRSPLATTV
301 MDFIHVPILP LNHALLAART RQLEDESVD GGAGAASAF PPRSSPCASS TPVAVGDFPD
361 CAYPPDAEPK DDAYPLYSDF QPPALKIKEE EEGAEASARS PRSYLVAGAN PAAFPDFPLG
421 PPPPLPPRAT PSRPGEAAVT AAPASASVSS ASSSGSTLEC ILYKAEGAPP QQGPFAPPPC
481 KAPGASGCLL PRDGLPSTSA SAAAAGAAPA LYPALGLNGL POLGYQAAVL KEGLPQVYPP
541 YLNYLRPDSE ASQSPQYSFE SLPQKICLIC GDEASGCHYG VLTGSCCKVF FKRAMAQHN
601 YLCAGRNDIC VDKIRRNCP ACRLRKCCQA GMVLGGRKEK KFNKVRVVRA LBAVALPQPL
661 GVPNESQALS QRFTFSPGQD IQLIPPLINL LMSIEPDVIY AGHDNTKPDOT SSSLLTSLNQ
721 LGERQLLSVV KWSKSLPGFR NLHIDDQITL IQYSWMSLMV FGLGWSYKH VSGQMLYFAP
781 DLILNEQRMK ESSFYSCLT MWQIPQEEFK LQVSQEEFLC MKVLLLLNTI FLEGLRSQTQ
841 FEEMRSSYIR ELIKAIGLRQ KGVVSSSQRF YQLTKLLDNL HDLVKQLHLY CLNTFIQSRA
901 LSVEFPMMMS EVIAAQLPKI LAGMVKPLLF HKK
```

Fig. 20

22/22

```

1  ctgaccagcg ccgcccctccc ccgcccccca cccaggaggt ggagatccct ccggtccagc
61  cacattcaac acccaactttc tcctccctct gccctatat tcccgaacc ccctcctcct
121  tcccttttcc ctccctccctg gagacggggg aggagaaaag gggagtccag tcgtcatgac
181  tgagctgaag gcaaagggtc ccggggctcc ccacgtggcg ggcggcccgc cctccccga
241  ggtcggatcc ccaactgctgt gtgcgccagc cgcagggtccg ttccggggga gccagacctc
301  ggacaccttg cctgaagttt cggccatacc tatctccctg gacgggctac tcttccctcg
361  gccctgccag ggacaggacc cctccgacga aaagacgcag gaccagcagt cgctgtcggg
421  cgtggagggc gcatattcca gagctgaagc tacaaggggt gctggaggca gcagttctag
481  tccccagaa aaggacagcg gactgctgga cagtgtcttg gacactctgt tggcgccctc
541  aggtcccggg cagagccaac ccagccctcc cgctgcgag gtcaccagct cttggtgcct
601  gtttggtccc gaacttccc aagatccacc ggctgcccc gccaccagc ggggtgtgtc
661  cccgctcatg agccgggtccg ggtgcaaggt tggagacagc tccgggacgg cagctgcccc
721  taaagtgtcg ccccgggggc tgaccaccag ccggcagctg ctgctcccg cctctgagag
781  ccctcactgg tccggggccc cagtgaagcc gtctccgcag gccgctgcgg tggaggttga
841  ggaggaggat ggctctgagt ccgaggagtc tgccgggtccg cttctgaagg gcaaacctcg
901  ggctctgggt ggcgcggcgg ctggaggagg agccgcggct gtcccgcgg gggcggcagc
961  aggaggcgct gccctggtcc ccaaggaaga ttcccgttc tcagcgcccc gggctgcctt
1021  ggtggagcag gacgcgcgga tggcgcccgg cgctccccg ctggccacca cggatgatga
1081  tttcattccc gtgctatccc tgctctcaa tcacgcctta ttggcagccc gcaactcgga
1141  gctgctgga gacgaaagtt acgacggcgg ggccggggct gccagcgctc ttgccccgcc
1201  gcggagttca ccctgtgcct cgtccacccc ggctcgtgta ggcgacttcc ccgactgcgc
1261  gtaccgcgcc gacgcgcgag ccaaggacga cgcgtaccct ctctatagcg acttccagcc
1321  gcccgctcta aagataaagg aggaggagga aggcgcggag gcctccgcgc gctccccgcg
1381  ttcctacctt gtggccggtg ccaaccccgc agccttccc gatttcccgt tggggccacc
1441  gcccccgtg ccgcccgcgag cgaccccatc cagaccgggg gaagcgggcg tgacggccgc
1501  acccgccagt gcctcagttc cgtctgcgtc ctctcgggg tcgacctgg agtgcatcct
1561  gtacaaagcg gagggcgcg cgcgccagca gggcccgttc gcgcgcgcgc cctgcaaggg
1621  gccgggcgcg agcggtgccc tgctcccgcg ggacggcctg ccctccacct ccgctctgcg
1681  cgccgcgcgc gggcgggccc ccgcgctcta cctgcactc ggctcaacg ggcctccgca
1741  gctcggctac caggccgcgc tgctcaagga gggcctgcc caggctctacc cgccctatct
1801  caactacctg aggcgggatt cagaagccag ccagagccca caatacagct tcgagtcatt
1861  acctcagaag atttggttaa tctgtgggga tgaagcatca ggctgtcatt atgggtgtct
1921  tacctgtggg agctgtaagg tcttctttta gagggcaatg gaagggcagc acaactactt
1981  atgtgctgga agaaatgact gcatcgttga taaaatccgc agaaaaaact gccagcatg
2041  tcgcttaga aagtgtgtc aggtggcat ggtccttggg ggtcgaaaat ttaaaaagtt
2101  caataaagtc agagtgtga gagcactgga tgctgttgct ctcccacagc cattgggcgt
2161  tccaaatgaa agccaagccc taagccagag attcactttt tcaccaggtc aagacataca
2221  gttgattcca ccaactgatc acctgttaat gagcattgaa ccagatgtga tctatgcagg
2281  acatgacaac acaaaacctg acacctccag ttctttgctg acaagtctta atcaactagg
2341  cgagaggcaa cttctttcag tagtcaagtg gtctaaatca ttgccagggt ttcgaaactt
2401  acatattgat gaccagataa ctctcattca gtattcttgg atgagcttaa tgggtgttgg
2461  tctaggtatg agatcctaca aacatgtcag tgggcagatg ctgtattttg cacctgatct
2521  aataactaaat gaacagcgga tgaaagaatc atcattctat tcattatgcc ttaccatgtg
2581  gcagatccca caggagtttg tcaaagctta agttagccaa gaagagttcc tctgtatgaa
2641  agtattgtta cttcttaata caattccttt ggaagggcta cgaagtcaaa cccagtttga
2701  ggagatgagg tcaagctaca ttagagagct catcaaggca attggtttga ggcaaaaagg
2761  agttgtgtcg agctcacagc gtttctatca acttaaaaaa cttcttgata acttgcatga
2821  tcttgatcaa caacttcac tgtaactgct gaatacattt atccagtccc gggcactgag
2881  tggtgaattt ccagaaatga tgtctgaagt tattgtgca caattacca agatattggc
2941  agggatggtg aaacccttc tctttcataa

```

Fig. 21

SEQUENCE LISTING

<110> Theragene Biomedical Laboratories GmbH

5 <120> Hormone-Hormone Receptor Complexes and Nucleic Acid
Constructs and Their Use in Gene Therapy

<130> 000065wo/JH/ml

10 <140>
<141>

<160> 19

15 <170> PatentIn Ver. 2.1

<210> 1
<211> 5753
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: vector pTGF36

25 <220>
<221> CDS
<222> (689)..(2071)

30 <400> 1
cgcggttgaca ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc 60
atagcccata tatggagttc cgcggttacat aacttacggt aaatggcccg cctggctgac 120
35 cgcccaacga ccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgcaa 180
tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaaactgcc cacttggcag 240
tacatcaagt gtatcatatg ccaagtacgc ccctattga cgtcaatgac ggtaaattggc 300
40 ccgcctggca ttatgccag tacatgacct tatgggactt tcctacttgg cagtacatct 360
acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 420
45 gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 480
tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 540
cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct ctctggctaa 600
50 ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc 660
aagcttgcat gccaatccg caaaggtt atg cag cgc gtg aac atg atc atg 712
Met Gln Arg Val Asn Met Ile Met
1 5

55 gca gaa tca cca ggc ctc atc acc atc tgc ctt tta gga tat cta ctc 760
Ala Glu Ser Pro Gly Leu Ile Thr Ile Cys Leu Leu Gly Tyr Leu Leu
10 15 20

60

	agt gct gaa tgt aca gtt ttt ctt gat cat gaa aac gcc aac aaa att	808
	Ser Ala Glu Cys Thr Val Phe Leu Asp His Glu Asn Ala Asn Lys Ile	
	25 30 35 40	
5	ctg aat cgg cca aag agg tat aat tca ggt aaa ttg gaa gag ttt gtt	856
	Leu Asn Arg Pro Lys Arg Tyr Asn Ser Gly Lys Leu Glu Glu Phe Val	
	45 50 55	
10	caa ggg aac ctt gag aga gaa tgt atg gaa gaa aag tgt agt ttt gaa	904
	Gln Gly Asn Leu Glu Arg Glu Cys Met Glu Glu Lys Cys Ser Phe Glu	
	60 65 70	
15	gaa gca cga gaa gtt ttt gaa aac act gaa aga aca act gaa ttt tgg	952
	Glu Ala Arg Glu Val Phe Glu Asn Thr Glu Arg Thr Thr Glu Phe Trp	
	75 80 85	
20	aag cag tat gtt gat gga gat cag tgt gag tcc aat cca tgt tta aat	1000
	Lys Gln Tyr Val Asp Gly Asp Gln Cys Glu Ser Asn Pro Cys Leu Asn	
	90 95 100	
25	ggc ggc agt tgc aag gat gac att aat tcc tat gaa tgt tgg tgt ccc	1048
	Gly Gly Ser Cys Lys Asp Asp Ile Asn Ser Tyr Glu Cys Trp Cys Pro	
	105 110 115 120	
30	ttt gga ttt gaa gga aag aac tgt gaa tta gat gta aca tgt aac att	1096
	Phe Gly Phe Glu Gly Lys Asn Cys Glu Leu Asp Val Thr Cys Asn Ile	
	125 130 135	
35	aag aat ggc aga tgc gag cag ttt tgt aaa aat agt gct gat aac aag	1144
	Lys Asn Gly Arg Cys Glu Gln Phe Cys Lys Asn Ser Ala Asp Asn Lys	
	140 145 150	
40	gtg gtt tgc tcc tgt act gag gga tat cga ctt gca gaa aac cag aag	1192
	Val Val Cys Ser Cys Thr Glu Gly Tyr Arg Leu Ala Glu Asn Gln Lys	
	155 160 165	
45	tcc tgt gaa cca gca gtg cca ttt cca tgt gga aga gtt tct gtt tca	1240
	Ser Cys Glu Pro Ala Val Pro Phe Pro Cys Gly Arg Val Ser Val Ser	
	170 175 180	
50	caa act tct aag ctc acc cgt gct gag act gtt ttt cct gat gtg gac	1288
	Gln Thr Ser Lys Leu Thr Arg Ala Glu Thr Val Phe Pro Asp Val Asp	
	185 190 195 200	
55	tat gta aat tct act gaa gct gaa acc att ttg gat aac atc act caa	1336
	Tyr Val Asn Ser Thr Glu Ala Glu Thr Ile Leu Asp Asn Ile Thr Gln	
	205 210 215	
60	agc acc caa tca ttt aat gac ttc act cgg gtt gtt ggt gga gaa gat	1384
	Ser Thr Gln Ser Phe Asn Asp Phe Thr Arg Val Val Gly Gly Glu Asp	
	220 225 230	
65	gcc aaa cca ggt caa ttc cct tgg cag gtt gtt ttg aat ggt aaa gtt	1432
	Ala Lys Pro Gly Gln Phe Pro Trp Gln Val Val Leu Asn Gly Lys Val	
	235 240 245	
70	gat gca ttc tgt gga ggc tct atc gtt aat gaa aaa tgg att gta act	1480
	Asp Ala Phe Cys Gly Gly Ser Ile Val Asn Glu Lys Trp Ile Val Thr	
	250 255 260	

gct gcc cac tgt gtt gaa act ggt gtt aaa att aca gtt gtc gca ggt 1528
 Ala Ala His Cys Val Glu Thr Gly Val Lys Ile Thr Val Val Ala Gly
 265 270 275 280

5 gaa cat aat att gag gag aca gaa cat aca gag caa aag cga aat gtg 1576
 Glu His Asn Ile Glu Glu Thr Glu His Thr Glu Gln Lys Arg Asn Val
 285 290 295

10 att cga att att cct cac cac aac tac aat gca gct att aat aag tac 1624
 Ile Arg Ile Ile Pro His His Asn Tyr Asn Ala Ala Ile Asn Lys Tyr
 300 305 310

15 aac cat gac att gcc ctt ctg gaa ctg gac gaa ccc tta gtg cta aac 1672
 Asn His Asp Ile Ala Leu Leu Glu Leu Asp Glu Pro Leu Val Leu Asn
 315 320 325

20 agc tac gtt aca cct att tgc att gct gac aag gaa tac acg aac atc 1720
 Ser Tyr Val Thr Pro Ile Cys Ile Ala Asp Lys Glu Tyr Thr Asn Ile
 330 335 340

ttc ctc aaa ttt gga tct ggc tat gta agt ggc tgg gga aga gtc ttc 1768
 Phe Leu Lys Phe Gly Ser Gly Tyr Val Ser Gly Trp Gly Arg Val Phe
 345 350 355 360

25 cac aaa ggg aga tca gct tta gtt ctt cag tac ctt aga gtt cca ctt 1816
 His Lys Gly Arg Ser Ala Leu Val Leu Gln Tyr Leu Arg Val Pro Leu
 365 370 375

30 gtt gac cga gcc aca tgt ctt cga tct aca aag ttc acc atc tat aac 1864
 Val Asp Arg Ala Thr Cys Leu Arg Ser Thr Lys Phe Thr Ile Tyr Asn
 380 385 390

35 aac atg ttc tgt gct ggc ttc cat gaa gga ggt aga gat tca tgt caa 1912
 Asn Met Phe Cys Ala Gly Phe His Glu Gly Gly Arg Asp Ser Cys Gln
 395 400 405

40 gga gat agt ggg gga ccc cat gtt act gaa gtg gaa ggg acc agt ttc 1960
 Gly Asp Ser Gly Gly Pro His Val Thr Glu Val Glu Gly Thr Ser Phe
 410 415 420

tta act gga att att agc tgg ggt gaa gag tgt gca atg aaa ggc aaa 2008
 Leu Thr Gly Ile Ile Ser Trp Gly Glu Glu Cys Ala Met Lys Gly Lys
 425 430 435 440

45 tat gga ata tat acc aag gta tcc cgg tat gtc aac tgg att aag gaa 2056
 Tyr Gly Ile Tyr Thr Lys Val Ser Arg Tyr Val Asn Trp Ile Lys Glu
 445 450 455

50 aaa aca aag ctc act taatgggacg ggtcgcgcgg ccgcgactct actagaggat 2111
 Lys Thr Lys Leu Thr
 460

ctttgtgaag gaaccttact tctgtggtgt gacataattg gacaaactac ctacagagat 2171

55 ttaaagctct aaggtaaata taaaattttt aagtgtataa tgtgttaaac tactgattct 2231

aattgtttgt gtattttaga ttccaaccta tggaactgat gaatgggagc agtggtggaa 2291

60 tgcctttaat gaggaaaacc tgttttgctc agaagaaatg ccatctagtg atgatgaggc 2351

tactgctgac tctcaacatt ctactcctcc aaaaaagaag agaaaggtag aagaccccaa 2411

ggacttttccct tcagaattgc taagtttttt gagtcattgct gtgttttagta atagaactct 2471
tgcttgcttt gctatttaca ccacaaagga aaaagctgca ctgctataca agaaaattat 2531
5 ggaaaaatat tctgtaacct ttataagtag gcataacagt tataatcata acatactgtt 2591
ttttcttact ccacacaggc atagagtgtc tgctattaat aactatgctc aaaaattgtg 2651
taccttttagc tttttaattt gtaaaggggt taataaggaa tatttgatgt atagtgcctt 2711
10 gactagagat cataatcagc cataccacat ttgtagaggt tttacttgct ttaaaaaacc 2771
tcccacacct cccctgaac ctgaaacata aaatgaatgc aattgttggt gttaacttgt 2831
15 ttattgcagc ttataatggt tacaataaa gcaatagcat cacaaatttc acaataaag 2891
catttttttc actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg 2951
tctggatccc cgggtacct ctagagcgaa ttaattcact ggccgtcggt ttacaacgtc 3011
20 gtgactggga aaacctggc gttaccaac ttaatcgct tgcagcacat cccctttcg 3071
ccagctggcg taatagcgaa gaggccgca ccgatcgccc ttccaacag ttgcgagcc 3131
25 tgaatggcg atggcgctg atgcggtatt ttctccttac gcatctgtgc ggtatttcac 3191
accgcatatg gtgcactctc agtacaatct gctctgatgc cgcatagtta agccagcccc 3251
gacaccgcc aacaccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt 3311
30 acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca ccgtcatcac 3371
cgaaacgcgc gagacgaaag ggggggtacc agcttcgtag ctagaacatc atgttctggg 3431
35 atatcagctt cgtagctaga acatcatgtt ctggtacccc cctcgtgata cgcctatttt 3491
tataggttaa tgtcatgata ataatggtt cttagacgtc aggtggcact tttcggggaa 3551
atgtgcgagg aaccttatt tgtttatttt tctaaatata ttcaaatatg tatccgctca 3611
40 tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc 3671
aacatttccg tgtcgccctt attccctttt ttgcggcatt ttgccttcct gtttttgctc 3731
45 acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt 3791
acatcgaact ggatctcaac agcggtaaga tcttgagag ttttcgcccc gaagaacgtt 3851
ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgacg 3911
50 ccgggcaaga gcaactcggc cgcgcgcatc actattctca gaatgacttg gttgagtact 3971
caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgtg 4031
55 ccataaccat gagtataac actgcggcca acttacttct gacaacgatc ggaggaccga 4091
aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt gatcggtggg 4151
aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg cctgtagcaa 4211
60 tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct tcccggaac 4271

aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc tcggcccttc 4331
cggtcggtg gtttattgct gataaatctg gagccggtga gcgtgggtct cgcggtatca 4391
5 ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac acgacgggga 4451
gtcaggcaac tatggatgaa cgaaatagac agatcgctga gatagggtgcc tcaactgatta 4511
10 agcattggta actgtcagac caagtttact catatatact ttagattgat ttaaaacttc 4571
atttttaatt taaaaggatc taggtgaaga tcctttttga taatctcatg accaaaatcc 4631
cttaacgtga gttttcgttc cactgagcgt cagaccccg agaaaagatc aaaggatcctt 4691
15 cttgagatcc ttttttctg cgcgtaactc gctgcttgca aacaaaaaaa ccaccgctac 4751
cagcgggtgt ttgtttgccg gatcaagagc taccaactct tttccgaag gtaactggct 4811
tcagcagagc gcagatacca aatactgttc ttctagtgtg gccgtagtta ggccaccact 4871
20 tcaagaactc tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg 4931
ctgccagtgg cgataagtcg tgtcttaccg ggttggaactc aagacgatag ttaccggata 4991
25 aggcgcagcg gtcgggctga acggggggtt cgtgcacaca gccagcttg gagcgaacga 5051
cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg cttccogaag 5111
ggagaaaggc ggacaggtat ccggttaagcg gcagggtcgg aacaggagag cgcacgaggg 5171
30 agcttccagg gggaaacgcc tggatcttt atagtcctgt cgggtttcgc cacctctgac 5231
ttgagcgtcg atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca 5291
35 acgcggcctt ttacgggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg 5351
cgttatcccc tgattctgtg gataaccgta ttaccgcctt tgagttagct gataccgctc 5411
gccgcagccg aacgaccgag cgcagcgagt cagttagcga ggaagcggaa gagcgcccaa 5471
40 tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg cacgacaggt 5531
ttcccgactg gaaagcgggc agtgagcgca acgcaattaa tgtgagttag ctcaactcatt 5591
45 aggcacccca ggctttacac ttatgcttc cggtcgtat gttgtgtgga attgtgagcg 5651
gataacaatt tcacacagga aacagctatg accatgatta cgccaagctc tctagagctc 5711
tagagctcta gagctctaga gagcttgcac gcctgcaggt cg 5753
50

<210> 2

<211> 461

<212> PRT

55 <213> Artificial Sequence

<223> Description of Artificial Sequence: vector pTGFG36

<400> 2

60 Met Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr
1 5 10 15

Ile Cys Leu Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr Val Phe Leu
 20 25 30
 5 Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn
 35 40 45
 Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu Cys
 50 55 60
 10 Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe Glu Asn
 65 70 75 80
 Thr Glu Arg Thr Thr Glu Phe Trp Lys Gln Tyr Val Asp Gly Asp Gln
 85 90 95
 15 Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly Ser Cys Lys Asp Asp Ile
 100 105 110
 Asn Ser Tyr Glu Cys Trp Cys Pro Phe Gly Phe Glu Gly Lys Asn Cys
 115 120 125
 Glu Leu Asp Val Thr Cys Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe
 130 135 140
 25 Cys Lys Asn Ser Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly
 145 150 155 160
 Tyr Arg Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala Val Pro Phe
 165 170 175
 30 Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu Thr Arg Ala
 180 185 190
 Glu Thr Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu Ala Glu
 195 200 205
 35 Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser Phe Asn Asp Phe
 210 215 220
 40 Thr Arg Val Val Gly Gly Glu Asp Ala Lys Pro Gly Gln Phe Pro Trp
 225 230 235 240
 Gln Val Val Leu Asn Gly Lys Val Asp Ala Phe Cys Gly Gly Ser Ile
 245 250 255
 45 Val Asn Glu Lys Trp Ile Val Thr Ala Ala His Cys Val Glu Thr Gly
 260 265 270
 50 Val Lys Ile Thr Val Val Ala Gly Glu His Asn Ile Glu Glu Thr Glu
 275 280 285
 His Thr Glu Gln Lys Arg Asn Val Ile Arg Ile Ile Pro His His Asn
 290 295 300
 55 Tyr Asn Ala Ala Ile Asn Lys Tyr Asn His Asp Ile Ala Leu Leu Glu
 305 310 315 320
 Leu Asp Glu Pro Leu Val Leu Asn Ser Tyr Val Thr Pro Ile Cys Ile
 325 330 335
 60 Ala Asp Lys Glu Tyr Thr Asn Ile Phe Leu Lys Phe Gly Ser Gly Tyr
 340 345 350

Val Ser Gly Trp Gly Arg Val Phe His Lys Gly Arg Ser Ala Leu Val
355 360 365

5 Leu Gln Tyr Leu Arg Val Pro Leu Val Asp Arg Ala Thr Cys Leu Arg
370 375 380

Ser Thr Lys Phe Thr Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His
385 390 395 400

10 Glu Gly Gly Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val
405 410 415

15 Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly
420 425 430

Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Ser
435 440 445

20 Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
450 455 460

<210> 3
25 <211> 78
<212> DNA
<213> Homo sapiens

<400> 3
30 ggggtaccag cttcgtagct agaacatcat gttctgggat atcagcttcg tagctagaac 60
atcatgttct ggtacccc 78

<210> 4
35 <211> 78
<212> DNA
<213> Homo sapiens

<400> 4
40 ggggtaccag aacatgatgt tctagctacg aagctgatat ccagaaacat gatgttctag 60
ctacgaagct ggtacccc 78

<210> 5
45 <211> 19
<212> DNA
<213> Homo sapiens

<400> 5
50 agcttgacct cgagcaagc 19

<210> 6
55 <211> 19
<212> DNA
<213> Homo sapiens

<400> 6
60 ggccgcttgc tcgaggtca 19

<210> 7
<211> 43
<212> DNA
<213> Homo sapiens
5
<400> 7
ggaattccgc aaaggttatg cagcgctga acatgatcat ggc 43

10 <210> 8
<211> 39
<212> DNA
<213> Homo sapiens

15 <400> 8
cgcgatcca ttaagtgagc ttgtttttt ccttaatcc 39

20 <210> 9
<211> 26
<212> DNA
<213> Homo sapiens

25 <400> 9
cgaggatcca gtcgtcatga ctgagc 26

30 <210> 10
<211> 41
<212> DNA
<213> Homo sapiens

35 <400> 10
gcagaattca ttataaaaac tcaagacctc ataatcctga c 41

40 <210> 11
<211> 20
<212> DNA
<213> Homo sapiens

45 <400> 11
ctcctcgagg tcgaccctgg 20

50 <210> 12
<211> 20
<212> DNA
<213> Homo sapiens

55 <400> 12
ccagggtcga ccccgaggag 20

60 <210> 13
<211> 5905
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: vector pTGFG53

<400> 13

	cgcggttgaca	ttgattattg	actagttatt	aatagtaatc	aattacgggg	tcattagttc	60
	atagcccata	tatggagttc	cgcggttacat	aacttacggt	aaatggcccc	cctggctgac	120
	cgcccaacga	cccccgccca	ttgacgtcaa	taatgacgta	tgttcccata	gtaacgccaa	180
5	tagggacttt	ccattgacgt	caatgggtgg	agtattttacg	gtaaactgcc	cacttggcag	240
	tacatcaagt	gtatcatatg	ccaagtacgc	cccctattga	cgtcaatgac	ggtaaatggc	300
	ccgcctggca	ttatgcccag	tacatgacct	tatgggactt	tcctacttgg	cagtacatct	360
	acgtattagt	catcgctatt	accatgggtga	tgcggttttg	gcagtacatc	aatgggcgtg	420
	gatagcgggt	tgactcacgg	ggattttccaa	gtctccaccc	cattgacgtc	aatgggagtt	480
10	tgttttgga	ccaaaatcaa	cgggactttc	caaaatgtcg	taacaactcc	gccccattga	540
	cgcaaatggg	cggtaggcgt	gtacgggtggg	aggctctatat	aagcagagct	ctctggctaa	600
	ctagagaacc	cactgcttac	tggcttatcg	aaattaatac	gactcactat	agggagaccc	660
	aagcttgcac	gccaatcccg	caaagggttat	gcagcgcggtg	aacatgatca	tggcagaatc	720
	accaggcctc	atcaccatct	gccttttagg	atatctactc	agtgtgtaac	gtacagtttt	780
15	tcttgatcat	gaaaaacgcca	acaaaattct	gaatcggcca	aagagggtata	atccaggtaa	840
	attggaagag	tttgttcaag	ggaaccttga	gagagaatgt	atggaagaaa	agtgtagttt	900
	tgaagaagca	cgagaagttt	ttgaaaaac	tgaagaaca	actgaatttt	ggaagcagta	960
	tgttgatgga	gatcagtggtg	agtccaatcc	atgttttaaat	ggcggcagtt	gcaaggatga	1020
	cattaattcc	tatgaatgtt	gggtgccctt	tggatttgaa	ggaagaact	gtgaattaga	1080
20	tgtaacatgt	aacattaaga	atggcagatg	cgagcagttt	tgtaaaaata	gtgctgataa	1140
	caaggtgggt	tgctcctgta	ctgagggata	tcgacttgca	gaaaaccaga	agtcctgtga	1200
	accagcagtg	ccatttccat	gtggaagagt	ttctgtttca	caaacttcta	agctcaccgg	1260
	tgctgagact	gtttttcctg	atgtggacta	tgtaaattct	actgaagctg	aaaccatttt	1320
	ggataacatc	actcaaagca	cccaatcatt	taatgacttc	actcgggttg	ttggtggaga	1380
25	agatgccaaa	ccaggtcaat	tcccttgga	ggttgttttg	aatggtaaag	ttgatgctat	1440
	ctgtggaggc	tctatcgtta	atgaaaaatg	gattgtaact	gctgccact	gtgttgaaac	1500
	tggtgttaaa	attacagttg	tcgcaggtga	acataatatt	gaggagacag	aacatacaga	1560
	gcaaaagcga	aatgtgattc	gaattattcc	tcaccacaac	tacaatgcag	ctattaataa	1620
	gtacaaccat	gacattgccc	ttctggaact	ggacgaaccc	ttagtgtcaa	acagctacgt	1680
30	tacacctatt	tgcattgctg	acaaggaata	cacgaacatc	ttcctcaaat	ttggatctgg	1740
	ctatgtaaat	ggctggggaa	gagtcctcca	caaagggaga	tcagctttag	ttcttcagta	1800
	ccttagagtt	ccacttggtg	accgagccac	atgtcttcga	tctacaaagt	tcaccatcta	1860
	taacaacatg	ttctgtgctg	gcttccatga	aggaggtaga	gattcatgtc	aaggagatag	1920
	tgggggaccc	catgttactg	aagtgggaag	gaccagtttc	ttactggaa	ttattagctg	1980
35	gggtgaagag	tgtgcaatga	aaggcaaatg	tggaaatata	accaaggtag	cccggtagt	2040
	caactggatt	aaggaaaaaa	caaagctcac	ttaatgggat	cggctcgagcg	gccgcgactc	2100
	tactagagga	tctttgtgaa	ggaaccttac	ttctgtgggtg	tgacataatt	ggacaaacta	2160
	cctacagaga	tttaaagctc	taaggtaaat	ataaaatttt	taagtgtata	atgtgttaaa	2220
	ctactgattc	taattgtttg	tgtatttttg	attccaacct	atggaactga	tgaatgggag	2280
40	cagtgggtgga	atgcctttta	tggagaaaac	gtgttttgct	cagaagaaat	gccatctagt	2340
	gatgatgagg	ctactgctga	ctctcaacat	tctactcctc	caaaaaagaa	gagaaaggta	2400
	gaagacccca	aggactttcc	ttcagaattg	ctaagttttt	tgagtcatgc	tgtgtttagt	2460
	aatagaactc	ttgcttgctt	tgctattttac	accacaaagg	aaaaagctgc	actgctatac	2520
	aagaaaaatta	tggaaaaata	ttctgtaacc	tttataagta	ggcataacag	ttataatcat	2580
45	aacatactgt	tttttcttac	tccacacagg	catagagtgt	ctgctattaa	taactatgct	2640
	caaaaattgt	gtacctttag	ctttttaatt	tgtaaaagggtg	ttataaagga	atatttgatg	2700
	tatagtgcct	tgactagaga	tcataatcag	ccataaccaca	ttttagagag	ttttacttgc	2760
	tttaaaaaac	ctcccacacc	tccccctgaa	cctgaaacat	aaaatgaatg	caattgttgt	2820
	tgttaacttg	tttattgcag	cttataatgg	ttacaaataa	agcaatagca	tcacaaattt	2880
50	cacaaataaa	gcattttttt	cactgcattc	tagttgtggt	ttgtccaaac	tcataaatgt	2940
	atcttatcat	gtctggatcc	ccggggggta	ccagcttcgt	agctagaaca	tcattgttctg	3000
	ggatatcagc	ttcgtagcta	gaacatcatg	ttctggtacc	cccgtcttag	agcgaattaa	3060
	ttcactggcc	gtcgtttttac	aacgtcgtga	ctgggaaaaac	cctggcggtta	cccaacttaa	3120
	tcgccttgca	gcacatcccc	ctttcgccag	ctggcgtaat	agcgaagagg	ccgcaccca	3180
55	tcgcctttcc	caacagttgc	gcagcctgaa	tggcgaaatg	cgctgatgc	ggatatttct	3240
	ccttacgcac	ctgtgcggta	tttcacaccg	catatgggtgc	actctcagta	caatctgctc	3300
	tgatgcccga	tagttaagcc	agccccgaca	cccgcacaac	cccgtgacg	cgccctgacg	3360
	ggcttgtctg	ctcccggcat	ccgcttacag	acaagctgtg	accgtctccg	ggagctgcat	3420
	gtgtcagagg	ttttaccggt	catcacggaa	acgcgcgaga	cgaaggggcg	gggtaccaga	3480
60	acatgatgtt	ctagctacga	agctgataac	cagaacatg	atgttctagc	tacgaagctg	3540
	gtacccccgc	ctcgtgatac	gcctattttt	ataggttaat	gtcatgataa	taatgggttc	3600
	ttagacgtca	ggtggcactt	ttcggggaaa	tgtgcgcgga	accctatttt	gtttattttt	3660

10

```

ctaaatacat tcaaataatgt atccgctcat gagacaataa ccctgataaa tgcttcaata 3720
atattgaaaa aggaagagta tgagtattca acattttccgt gtcgccctta tttcccttttt 3780
tgcggcattt tgccttcctg tttttgctca cccagaaacg ctggtgaaag taaaagatgc 3840
tgaagatcag ttgggtgcac gagtgggtta catcgaaactg gatctcaaca gcggtaaagt 3900
5 ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta aagtctgtct 3960
atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca 4020
ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcacc ttacggatgg 4080
catgacagta agagaattat gcagtgtctgc cataaccatg agtgataaca ctgcggccaa 4140
cttacttctg acaacgatcg gaggaccgaa ggagctaaac gcttttttgc acaacatggg 4200
10 ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga 4260
gatcgctgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg 4320
cgaactactt actctagctt cccggcaaca attaatagac tggatggagg cggataaagt 4380
tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg 4440
agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc 4500
15 ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca 4560
gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc 4620
atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat 4680
cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgctc 4740
agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg 4800
20 ctgcttgcaa acaaaaaaac caccgtacc agcgttggtt tgtttgccgg atcaagagct 4860
accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct 4920
tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct 4980
cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg 5040
gttggactca agacgatagt tacggataag gcgcagcggg cgggctgaac ggggggttgc 5100
25 tgcacacagc ccagcttggg gcgaacgacc tacaccgaac tgagatacct acagcgtgag 5160
ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 5220
agggtcgga caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 5280
agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgatgat ctgcgcaggg 5340
gggaggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttctt ggccttttgc 5400
30 tggccttttg ctcacatgtt ctttctcgct ttatcccctt attctgtgga taaccgtatt 5460
accgcttttg agtgagctga taccgctcgc cgacgccgaa cgaccgagcg cagcgagtca 5520
gtgagcgagg aagcggaaga gcgcccaata cgcaaacgc ctctccccgc gcgttgccg 5580
attcattaat gcagctggca cgacagggtt cccgactgga aagcgggcag tgagcgcaac 5640
gcaattaatg tgagttagct cactcattag gcaccccagg ctttacactt tatgcttccg 5700
35 gctcgattgt tgtgtggaat tgtgagcggt taacaatttc acacaggaac cagctatgac 5760
catgattacg ccaagctctc tagagctcta gagctctaga gctctagaga gcttgcatgc 5820
cggggtacca gcttcgtagc tagaacatca tgttctggga tatcagcttc gtagctagaa 5880
catcatgttc tggtagcccc gtcga 5905

40
<210> 14
<211> 6052
<212> DNA
<213> Artificial Sequence

45
<220>
<223> Description of Artificial Sequence: vector pTGF64

<400> 14
50 cgcgttgaca ttgattattg actagttatt aatagtaatc aattacgggg tcattagtgc 60
atagcccata tatggagttc cgcgttacat aacttacggt aaatggccc cctggctgac 120
cgccaacga ccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa 180
tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag 240
tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc 300
55 ccgcctggca ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct 360
acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 420
gatagcgggt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 480
tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 540
cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct ctctggctaa 600
60 ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc 660
aagcttgcac gccaatccg caaagggtat gcagcgcgtg aacatgatca tggcagaatc 720
accaggcctc atcaccatct gccttttagg atatctactc agtgctgaat gtacagtttt 780

```

	tcttgatcat	gaaaacgcc	acaaaattct	gaatcggcca	aagaggtata	attcaggtaa	840
	attggaagag	tttgttcaag	ggaaccttga	gagagaatgt	atggaagaaa	agtgtagttt	900
	tgaagaagca	cgagaagttt	ttgaaaacac	tgaaagaaca	actgaatttt	ggaagcagta	960
	tggtgatgga	gatcagtggt	agtccaatcc	atgttttaaat	ggcggcagtt	gcaaggatga	1020
5	cattaattcc	tatgaatgtt	ggtgtccctt	tggaatttgaa	ggaaagaact	gtgaattaga	1080
	tgtaacatgt	aacattaaga	atggcagatg	cgagcagttt	tgtaaaaaata	gtgctgataa	1140
	caaggtggtt	tgctcctgta	ctgagggata	tcgacttgca	gaaaaccaga	agtcctgtga	1200
	accagcagtg	ccatttccat	gtggaagagt	ttctgtttca	caaacttcta	agctcaccgg	1260
	tgctgagact	gtttttcctg	atgtggacta	tgtaaattct	actgaagctg	aaaccatttt	1320
10	ggataaacat	actcaaaagca	cccaatcatt	taatgacttc	actcgggttg	ttggtggaga	1380
	agatgccaaa	ccaggtcaat	tcccttgcca	ggttggtttg	aatggtaaag	ttgatgcatt	1440
	ctgtggaggc	tctatcgtaa	atgaaaaatg	gattgttaact	gctgccct	gtgttgaaac	1500
	tggtgttaaa	attacagttg	tcgcaggtga	acataatatt	gaggagacag	aacatacaga	1560
	gcaaaagcga	aatgtgattc	gaattattcc	tcaccacaac	tacaatgcag	ctattaataa	1620
15	gtacaacctt	gacattgccc	ttctggaact	ggacgaacct	ttagtgtctaa	acagctactg	1680
	tacacctatt	tgcatgtctg	acaaggaata	cacgaacatc	ttcctcaaat	ttggatctgg	1740
	ctatgtaagt	ggctggggaa	gagtcctcca	caaagggaga	tcagctttag	ttcttcagta	1800
	ccttagagtt	ccacttggtg	accgagccac	atgtcttcga	tctacaaagt	tcaccatcta	1860
	taacaacatg	ttctgtgctg	gcttccatga	aggaggtaga	gattcatgtc	aaggagatag	1920
20	tgggggaccc	catgttactg	aagtggaaag	gaccagtttc	ttacttgga	ttattagctg	1980
	gggtgaagag	tgtgcaatga	aaggcaataa	tggaatatat	accaaggtat	cccggatgt	2040
	caactggatt	aaggaaaaaa	caaagctcac	ttaatgggat	cggtcgagcg	gccgcgactc	2100
	tactagagga	tctttgtgaa	ggaaccttac	ttctgtgggt	tgacataatt	ggacaaacta	2160
	cctacagaga	tttaaagctc	taaggtaaat	ataaaatttt	taagtgtata	atgtgttaaa	2220
25	ctactgattc	taattgtttg	tgtattttag	attccaacct	atggaactga	tgaatgggag	2280
	cagtggttga	atgcctttaa	tgaggaaaac	ctgttttgct	cagaagaaat	gccatctagt	2340
	gatgatgagg	ctactgctga	ctctcaacat	tctactcctc	caaaaaagaa	gagaaaggta	2400
	gaagacccca	aggactttcc	ttcagaattg	ctaagttttt	tgagtcatgc	tgtgtttagt	2460
	aatagaactc	ttgcttgctt	tgctatttcc	accacaaagg	aaaaagctgc	actgctatac	2520
30	aagaaaatta	tggaataata	ttctgtaacc	tttataagta	ggcataaacg	ttataatcat	2580
	aacatactgt	tttttcttac	tcacacacag	catagagtgt	ctgctattaa	taactatgct	2640
	caaaaattgt	gtacctttag	ctttttaatt	tgtaaagggg	ttaataagga	atatttgatg	2700
	tatagtgcct	tgactagaga	tcataatcag	ccataaccaca	ttttagagag	ttttacttgc	2760
	tttaaaaaac	ctccacacac	tccccctgaa	cctgaaacat	aaaatgaatg	caattgtttg	2820
35	tgtaacttgg	tttattgcag	cttataatgg	ttacaaataa	agcaatagca	tcacaaattt	2880
	cacaaataaa	gcattttttt	cactgcattc	tagttgtggt	ttgtccaaac	tcacatcatg	2940
	atcttatcat	gtctggatcc	ccggggggta	ccagcttcgt	agctagaaca	tcagtgtctg	3000
	ggatatacag	ttcgtagcta	gaacatcatg	ttctggtacc	cccctctaga	gcgaattaat	3060
	tcactggccg	tcgttttaca	acgtcgtgac	tgggaaaacc	ctggcggttac	ccaacttaat	3120
40	cgccttgagc	cacatccccc	tttcgccacc	tggcgttaata	gcgaagaggc	ccgcaccgat	3180
	cgcccttccc	aacagttgag	cagcctgaat	ggcgaatggc	ggggtaccag	cttcgtagct	3240
	agaacatcat	gttctgggat	atcagcttcg	tagctagaac	atcatgttct	ggtaccccg	3300
	ctgatgcggt	atcttctcct	tacgcatctg	tgccgtattt	cacaccgcat	atgggtgcact	3360
	ctcagtacaa	tctgctctga	tgccgcatag	ttaagccagc	cccgacaccc	gccaacaccc	3420
45	gctgacgcgc	cctgacgggc	ttgtctgctc	ccggcatccg	cttacagaca	agctgtgacc	3480
	gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	cgcgagacga	3540
	aagggcacca	gaacatgatg	ttctagctac	gaagctgata	tcccagaaca	tgatgttcta	3600
	gctacgaagc	tggtaccccg	cctcgtgata	cgcctatttt	tataggttaa	tgtcatgata	3660
	ataatgggtt	cttagacgtc	aggtggcact	tttcggggaa	atgtgcgagg	aacccttatt	3720
50	tgtttatttt	tctaaataca	ttcaaatatg	tatccgctca	tgagacaata	accctgataa	3780
	atgcttcaat	aatattgaaa	aaggaagagt	atgagtattc	aacatttccg	tgctgccttt	3840
	attccctttt	ttgcggcatt	ttgccttcc	gtttttgctc	acccagaaac	gctggtgaaa	3900
	gtaaaagatg	ctgaagatca	gttgggtgca	cgagtgggtt	acatcgaact	ggatctcaac	3960
	agcggtaaga	tccttgagag	ttttcgcccc	gaagaaacgt	ttccaatgat	gagcactttt	4020
55	aaagttctgc	tatgtggcgc	ggtattatcc	cgatttgacg	ccgggcaaga	gcaactcggt	4080
	cgccgcatac	actattctca	gaatgacttg	gttgagtact	caccagtcac	agaaaagcat	4140
	cttacggatg	gcatgacagt	aagagaatta	tgcatgctg	ccataaccat	gagtgataac	4200
	actgcggcca	acttacttct	gacaacgatc	ggaggaccga	aggagctaac	cgcttttttg	4260
	cacaacatgg	gggatcatgt	aaactgcctt	catcggtggg	aaccggagct	gaatgaagcc	4320
60	ataccaaacg	acgagcgtga	caccacgatg	cctgtagcaa	tggaacaac	gttgcgcaaa	4380
	ctattaactg	gcgaactact	tactctagct	tcccggcaac	aattaataga	ctggatggag	4440
	gcggataaag	ttgcaggacc	acttctgcgc	tcggcccttc	cggctggctg	gtttattgct	4500

gataaatctg gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggcccagat 4560
 ggtaagccct cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa 4620
 cgaaatagac agatcgctga gataggtgcc tcaactgatta agcattggta actgtcagac 4680
 caagtttact catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc 4740
 5 taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcggtc 4800
 cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg 4860
 cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcgtggtt ttgtttgccc 4920
 gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca 4980
 aatactgtcc ttctagtgtg gccgtagtta ggccaccact tcaagaactc tgtagcaccg 5040
 10 cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg 5100
 tgtcttaccg gggttgactc aagacgatag ttaccggata aggcgcagcg gtcgggctga 5160
 acgggggggt cgtgcacaca gccagcttg gagcgaacga cctacaccga actgagatac 5220
 ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggat 5280
 ccggtgaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc 5340
 15 tgggtatctt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga 5400
 tgctcgctcag gggggcggag cctatgaaa aacgccagca acgcggcctt tttacggttc 5460
 ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg 5520
 gataaccgta ttaccgcctt tgagttagct gataccgctc gccgcagccg aacgaccgag 5580
 cgcagcgagt cagttagcga ggggtaccag aacatgatgt tctagctacg aagctgatat 5640
 20 ccagaacat gatgttctag ctacgaagct ggtaccccag cggaagagcg cccaatacgc 5700
 aaaccgcctc tccccgcgcg ttggccgatt cattaatgca gctggcacga caggtttccc 5760
 gactggaaag cgggcagtga gcgcaacgca attaatgtga gttagctcac tcattaggca 5820
 ccccaggctt tacactttat gcttccggct cgtatgttgt gtggaattgt gagcgggata 5880
 caatttcaca caggaaacag ctatgaccat gattacgcca agctctctag agctctagag 5940
 25 ctctagagct ctagagagct tgcattgccg ggtaccagct tcgtagctag aacatcatgt 6000
 tctgggatat cagcttcgta gctagaacat catgttcttg taccgccgtc ga 6052

<210> 15
 30 <211> 4344
 <212> DNA
 <213> Artificial Sequence

<220>
 35 <223> Description of Artificial Sequence: vector pTGFG67

<400> 15
 cgcgttgaca ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc 60
 atagcccata tatggagtgc cgcgttacat aacttacggt aaatggccc cctggctgac 120
 40 cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa 180
 tagggacttt ccattgacgt caatgggtgg agtattttac gtaaaactgc cacttggcag 240
 tacatcaagt gtatcatatg ccaagtacgc ccctatttga cgtcaatgac ggtaaatggc 300
 ccgcctggca ttatgccag tacatgacct tatgggactt tcctacttgg cagtacatct 360
 acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 420
 45 gatagcgggt ttgactcacg ggatttccaa gtctccaccc cattgacgtc aatgggagt 480
 tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 540
 cgcaaatggg cggtaggcgt gtacgggtgg aggtctatat aagcagagct ctctggctaa 600
 ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc 660
 aagcttgacc tcgagcaagc ggccgcgact ctactagagg atctttgtga aggaacctta 720
 50 cttctgtggt gtgacataat tggacaaact acctacagag atttaaagct ctaaggtaaa 780
 tataaaattt ttaagtgtat aatgtgttaa actactgatt ctaattgttt gtgtatttta 840
 gattccaacc tatggaactg atgaatggga gcagtggtgg aatgccttta atgaggaaaa 900
 cctgttttgc tcagaagaaa tgccatctag tgatgatgag gctactgctg actctcaaca 960
 ttctactcct ccaaaaaaga agagaagggt agaagacccc aaggactttc cttcagaatt 1020
 55 gctaagtttt ttgagtcagt ctgtgtttag taatagaact cttgcttgct ttgctattta 1080
 caccacaaag gaaaaagctg cactgctata caagaaaaat atctctgaac 1140
 ctttataagt aggcataaca gttataatca taacatactg ttttttctta ctccacacag 1200
 gcatagagtg tctgctatta ataactatgc tcaaaaattg tgtaccttta gctttttaat 1260
 ttgtaaaagg gttaataagg aatatttgat gtatagtgcc ttgactagag atcataatca 1320
 60 gccataccac atttgtagag gttttacttg ctttaaaaaa cctccacac ctccccctga 1380
 acctgaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg 1440
 gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt tcaactgcatt 1500


```

ctagtgtgtg tttgtccaaa ctcatcaatg tatcttatca tgtctggatc cccgggtacc 1560
ctetagagcg aattaattca ctggccgctcg ttttacaacg tcgtgactgg gaaaaccctg 1620
gcgttaccca acttaatcgc ctgacgacac atcccccttt cgccagctgg cgtaatagcg 1680
aagaggcccc caccgatcgc ccttcccaac agttgcgcag cctgaatggc gaatggcgcc 1740
5  tgatgcggtg ttttctcctt acgcatctgt gcggtatttc acaccgcata tgggtgacct 1800
tcagtacaat ctgctctgat gccgcatagt taagccagcc ccgacaccgc ccaacaccgc 1860
ctgacgcgcc ctgacgggct tgtctgctcc cgcatccgc ttacagacaa gctgtgacct 1920
tctccgggag ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgagacgaa 1980
agggggggta ccagcttcgt agctagaaca tcatgttctg ggatatcagc ttcgtagcta 2040
10  gaacatcatg ttctggtacc cccctcgtga tacgcctatt tttataggtt aatgtcatga 2100
ttcttagacg tcagggtggc cttttcgggg aaatgtgcgc ggaaccctta 2160
tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa taaccctgat 2220
aaatgcttca ataatttga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc 2280
ttattccctt ttttgcgga ttttgcttc ctgtttttgc tccccagaa acgctggtga 2340
15  aagtaaaaga tgctgaagat cagttgggtg cagcagtggt ttacatcgaa ctggatctca 2400
acagcggtaa gatccttgag agttttcgcc ccgaagaacg ttttccaatg atgagcactt 2460
ttaagttctt gctatgtggc gcggtattat cccgtattga cgccgggcaa gagcaactcg 2520
gtcgccgcat acactattct cagaatgact tgggttagta ctaccagtc acagaaaagc 2580
atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtata 2640
20  acactgcgcc caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt 2700
atggtaacat gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag 2760
ccataccaaa cgacgagcgt gacaccacga tgctgtagc aatggcaaca acgttgcgca 2820
aactattaac tggcgaacta ctactctag cttcccggca acaattaata gactggatgg 2880
agggcgataa agttgcagga ccacttctgc gtcggccctt tccggctggc tgggtttattg 2940
25  ctgataaatc tggagccggt gagcgtgggt ctgcggttat cattgcagca ctggggccag 3000
atggtaagcc ctcccgatc gtagttatct acacgacggg gagtcaggca actatggatg 3060
aacgaaatag acagatcgct gagataggtg cctcactgat taagcatttg taactgtcag 3120
accaagttta ctcatatata cttagattg atttaaaact tcatTTTTaa tttaaaagga 3180
tctaggtgaa gatccttttt gataatctca tgacaaaaat cccttaacgt gagttttcgt 3240
30  tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cttttttttc 3300
tgccgctaag ctgctgcttg caaacaacaaa aaccacgct accagcggtg gtttgtttgc 3360
cggatcaaga gctaccaact ctttttccga aggttaactgg cttcagcaga gcgcagatac 3420
caaatactgt tcttctagt tagccgtagt taggccacca cttcaagaac tctgtagcac 3480
cgctacata cctcgtctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 3540
35  cgtgtcttac cgggttgagc tcaagacgat agttaccgga taaggcgag cggtcggtct 3600
gaacgggggg ttcgtgcaca cagccagct tggagcgaac gacctacacc gaactgagat 3660
acctacagcg tgagctatga gaaagcgcca cgcttccga agggagaaag gcggacaggt 3720
atccggttaag cggcagggtc ggaacaggag agcgacagag ggagcttcca gggggaaacg 3780
cctggtatct ttatagctct gtcgggtttc gccacctctg acttgagcgt cgatttttgt 3840
40  gatgctcgtc agggggcgcg agcctatgga caacgcggcc tttttacggg 3900
tctctggcct ttgctggcct tttgctcaca tgttcttttc tgcgttatcc cctgattctg 3960
tgataaccg tattaccgcc tttgagttag ctgataccgc tcgccgcagc cgaacgaccg 4020
agcgacgca gtcagttagc gaggaaagcg aagagcgccc aatacgcaaa ccgcctctcc 4080
ccgcgcggtg gccgattcat taatgcagct ggcacgacag gtttcccgc tggaagcggt 4140
45  gcagttagcg caacgcaatt aatgtgagtt agctcactca ttaggcaccc caggctttac 4200
actttatgct tccgctcgt atgttgtgtg gaattgtgag cggataacaa tttcacacag 4260
gaaacagcta tgaccatgat tacgccaagc tctctagagc tctagagctc tagagctcta 4320
gagagcttgc atgcctgcag gtcg 4344

50  <210> 16
    <211> 4496
    <212> DNA
    <213> Artificial Sequence

55  <220>
    <223> Description of Artificial Sequence: vector pTGF82

    <400> 16
60  cgcgttgaca ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc 60
    atagcccata tatggagttc cgcgttacat aacttacggt aaatggccc cctggctgac 120
    cgcccaacga ccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgcca 180

```

	tagggacttt	ccattgacgt	caatgggtgg	agtattttacg	gtaaactgcc	cacttggcag	240
	tacatcaagt	gtatcatatg	ccaagtacgc	cccctattga	cgatcaatgac	ggtaaattggc	300
	ccgcctggca	ttatgcccg	tacatgacct	tatgggactt	tcctacttgg	cagtacatct	360
	acgtattagt	catcgctatt	accatgggtga	tgcggttttg	gcagtacatc	aatgggctg	420
5	gatagcggtt	tgactcacgg	ggattttccaa	gtctccaccc	cattgacgtc	aatgggagtt	480
	tgttttggca	ccaaaatcaa	cgggactttc	caaaatgtcg	taacaactcc	gccccattga	540
	cgcaaatggg	cggtaggcgt	gtacgggtggg	aggtctatat	aagcagagct	ctctggctaa	600
	ctagagaacc	cactgcttac	tggtcttatcg	aaattaatac	gactcactat	aggagagacc	660
	aagcttgacc	tcgagcaagc	ggccgcgact	ctactagagg	atctttgtga	aggaacctta	720
10	cttctgtggt	gtgacataat	tggaacaaat	acctacagag	atttaaagct	ctaaggtaaa	780
	tataaaat	ttaagtgtat	aatgtgttaa	actactgatt	ctaattgttt	gtgtatttta	840
	gattccaacc	tatggaactg	atgaatggga	gcagtgggtg	aatgccttta	atgaggaaaa	900
	cctgttttgc	tcagaagaaa	tgccatctag	tgatgatgag	gctactgctg	actctcaaca	960
	ttctactcct	ccaaaaaaga	agagaaaggt	agaagacccc	aaggactttc	cttcagaatt	1020
15	gctaagtttt	ttgagtcagt	ctgtgttttg	taatagaact	cttgcttgct	ttgctattta	1080
	caccacaaag	gaaaaagctg	cactgctata	caagaaaatt	atggaaaaat	attctgtaac	1140
	ctttataagt	aggcataaca	gttataatca	taacatactg	ttttttctta	ctccacacag	1200
	gcatagagtg	tctgctatta	ataactatgc	tcaaaaattg	tgtaccttta	gctttttaat	1260
	ttgtaaaggg	gttaataaag	aatatttgat	gtatagtggc	ttgactagag	atcataatca	1320
20	gccataccac	atttgtagag	gttttacttg	ctttaaaaaa	cctcccacac	ctccccctga	1380
	acctgaaaca	taaaatgaat	gcaattgttg	ttgttaactt	gtttattgca	gcttataatg	1440
	gttacaaata	aagcaatagc	atcacaaatt	tcacaaataa	agcatttttt	tactgtcatt	1500
	ctagtgtggt	tttgtccaaa	ctcatcaatg	tatcttatca	tgtctggatc	ccgggggggt	1560
	accagcttcg	tagctagaac	atcatgttct	gggatatcag	cttcgtagct	agaacatcat	1620
25	gttctggtag	ccccctctag	agcgaattaa	ttcactggcc	gtcgttttac	aacgtcgtga	1680
	ctgggaaaac	cctggcggtta	cccaacttaa	tcgccttgca	gcacatcccc	ctttcgccag	1740
	ctggcgtaat	agcgaagagg	cccgcaccga	tcgccccttc	caacagttgc	gcagcctgaa	1800
	tggcgaatgg	cgctgatgac	ggtattttct	ccttacgcat	ctgtgcggta	tttcacaccg	1860
	catatggtgc	actctcagta	caatctgctc	tgatgccgca	tagttaagcc	agccccgaca	1920
30	cccggccaaca	cccgctgacg	cgccctgacg	ggcttgctcg	ctcccggcat	ccgctttacag	1980
	acacgaatgtg	accgtctccg	ggagctgcat	gtgtcagagg	ttttcacctg	catcaccgaa	2040
	acgcgcgaga	cgaaagggcg	gggtaccaga	acatgatgtt	ctagctacga	agctgatatc	2100
	ccagaacatg	atgttctagc	tacgaagctg	gtaccccggc	ctcgtgatac	gcctattttt	2160
	ataggttaat	gtcatgataa	taatggtttc	ttagacgtca	ggtggcactt	ttcggggaaa	2220
35	tggtcgcgga	acccctattt	gtttattttt	ctaaatacat	tcaaatatgt	atccgtctac	2280
	gagacaataa	ccctgataaa	tgcttcaata	atattgaaaa	aggaagagta	tgagtattca	2340
	acatttccgt	gtcgccttta	ttcccttttt	tgccgcat	tgcccttctg	tttttgctca	2400
	cccagaaacg	ctggtgaaag	taaaagatgc	tgaagatcag	ttgggtgcac	gagtggttta	2460
	catcgaactg	gatctcaaca	gcggtaagat	ccttgagagt	tttcgccccg	aagaacgttt	2520
40	tcacaatgat	agcactttta	aagttctgct	ctgtggcgcg	gtattatccc	gtattgacgc	2580
	cgggcaagag	caactcggtc	gccgcataca	ctattctcag	aatgacttgg	ttgagtactc	2640
	accagtcaca	gaaaagcatc	ttacggatgg	catgacagta	agagaattat	gcagtgtctg	2700
	cataaccatg	agtataaaca	ctgcggccaa	cttacttctg	acaacgatcg	gaggaccgaa	2760
	ggagctaacc	gcttttttgc	acaacatggg	ggatcatgta	actcgcttg	atcggtggga	2820
45	accggagctg	aatgaagcca	taccaaacga	cgagcgtgac	accacgatgc	ctgtagcaat	2880
	ggcaacaacg	ttgcgcaaac	tattaaactg	cgaactactt	actctagctt	cccggcaaca	2940
	attaatagac	tggatggagg	cggataaagt	tgaggaccca	cttctgcgct	cggcccttcc	3000
	ggctggctgg	tttattgctg	ataaatctgg	agccgggtgag	cgtgggtctc	gcggtatcat	3060
	tgacgactg	gggccagatg	gtaagccctc	ccgtatcgta	gttatctaca	cgacggggag	3120
50	tcaggcaact	atggatgaac	gaaatagaca	gatcgctgag	ataggtgcct	cactgattaa	3180
	gcattggtta	ctgtcagacc	aagtttactc	atatatactt	tagattgatt	taaaacttca	3240
	tttttaattt	aaaaggatct	aggtgaagat	cctttttgat	aatctcatga	ccaaaatccc	3300
	ttaacgtgag	ttttctgtcc	actgagcgtc	agaccccgta	gaaaagatca	aaggatcttc	3360
	ttgagatcct	tttttctgct	gcgtaatctg	ctgcttgcaa	acaaaaaac	caccgctacc	3420
55	agcggctggt	tggttgccgg	atcaagagct	accactctt	tttccgaagg	taactggctt	3480
	cagcagagcg	cagataccaa	atactgtcct	tctagtgtag	ccgtagttag	gccaccactt	3540
	caagaactct	gtagcaccgc	ctacatacct	cgctctgcta	atcctgttac	cagtggctgc	3600
	tgccagtgcc	gataagtcgt	gtcttaccgg	gttgagactca	agacgatagt	taccggataa	3660
	ggcgagcg	tcgggctgaa	cggggggttc	gtgcacacag	cccagcttgg	agcgaacgac	3720
60	ctacaccgaa	ctgagatacc	tacagcgtga	gctatgagaa	agcgccacgc	ttcccgaagg	3780
	gagaaaggcg	gacaggtatc	cggttaagcg	cagggctcga	acaggagagc	gcacgagggg	3840
	gcttccagg	ggaaacgcct	ggtatcttta	tagtctgtc	gggtttcgcc	acctctgact	3900

15

```

      tgagcgctcga tttttgtgat gctcgtcagg ggggaggagc ctatggaaaa acgccagcaa 3960
      cgcgccctttt ttacgggttcc tggccttttt ctggcctttt gctcacatgt tctttcctgc 4020
      gttatccctt gattctgtgg ataaccgtat taccgccttt gagtgagctg ataccgctcg 4080
      ccgcagccga acgaccgagc gcagcgagtc agtgagcgag gaagcggaag agcgcccaa 4140
5      acgcaaaccg cctctccccg cgcgttgccc gattcattaa tgcagctggc acgacaggtt 4200
      tccccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc tcaactcatta 4260
      ggcaccccgag gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa ttgtgagcgg 4320
      ataacaattt cacacaggaa acagctatga ccatgattac gccaaagctct ctagagctct 4380
      agagctctag agctctagag agcttgcatg ccgggggtacc agcttcgtag ctagaacatc 4440
10     atgttctggg atatcagctt cgtagctaga acatcatggt ctggtacccc ggtcga 4496

```

<210> 17

<211> 4644

15 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: vector pTGFG95

20

<400> 17

```

      cgcgttgaca ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc 60
      atagcccata tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac 120
      cgcccaacga cccccgcca ttgacgtcaa taatgacgta tgttccata gtaacgcaa 180
25     tagggacttt ccattgacgt caatgggtgg agtattttacg gtaaaactgcc cacttggcag 240
      tacatcaagt gtatcatatg ccaagtagcg cccctattga cgtcaatgac ggtaaatggc 300
      ccgcctggca ttatgccag tacatgacct tatgggactt tctacttgg cagtacatct 360
      acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 420
      gatagcgggt tgactcacgg ggatttccaa gtctccacc cattgacgtc atggggagtt 480
30     tgttttgcca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 540
      cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct ctctggctaa 600
      ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc 660
      aagcttgacc tcgagcaagc ggccgcgact ctactagagg atctttgtga aggaacctta 720
      cttctgtggt gtgacataat tggacaaact acctacagag atttaaagct ctaaggtaaa 780
35     tataaaattt ttaagtgtat aatgtgttaa actactgatt ctaattgttt gtgtatttta 840
      gattccaacc tatggaactg atgaatggga gcagtgggtg aatgccttta atgaggaaaa 900
      cctgttttgc tcagaagaaa tgccatctag tgatgatgag gctactgctg actctcaaca 960
      ttctactcct ccaaaaaaga agagaaagggt agaagacccc aaggactttc cttcagaatt 1020
      gctaaagttt ttgagtcagt ctgtgtttag taatagaact cttgcttgct ttgctattta 1080
40     caccacaaag gaaaaagctg cactgctata caagaaaatt atggaaaaat attctgtaac 1140
      ctttataagt aggcataaca gttataatca taacatactg tttttctta ctccacacag 1200
      gcatagagtg tctgctatta ataactatgc tcaaaaattg tgtaccttta gctttttaat 1260
      ttgtaaaagg gttaataagg aatatttgat gtatagtgcc ttgactagag atcataatca 1320
      gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac ctccccctga 1380
45     acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg 1440
      gttacaaata aagcaatagc atcacaaatt tcacaaataa agcattttt tcaactgcatt 1500
      ctagtgtggt tttgtccaaa ctcatcaatg tatcttatca tgtctggatc cccggggggt 1560
      accagcttcg tagctagaac atcatgttct gggatatcag cttcgtagct agaacatcat 1620
      gttctgttac cccctctag agcgaattaa ttactggcc gtcggtttac aacgtcgtga 1680
50     ctgggaaaac cctggcgtaa cccaacttaa tcgccttgca gcacatcccc ctttcgccag 1740
      ctggcgtaat agcgaagagg cccgcaccga tcgccttcc caacagttgc gcagcctgaa 1800
      tggcgtaatg cggggtagca gcttcgtagc tagaacatca tgttctggga tatcagcttc 1860
      gtagctagaa catcatgttc tggtagcccg cctgatgcgg tattttctcc ttacgcatct 1920
      gtgcggtatt tcacaccgca tatggtgcac tctcagtaca atctgctctg atgccgcata 1980
55     gttaagccag cccgcacacc cgccaacacc cgctgacgag ccctgacggg cttgtctgct 2040
      cccggcatcc gcttacagac aagctgtgac cgtctccggg agctgcatgt gtcagaggtt 2100
      ttcaccgtca tcaccgaaac gcgcgagacg aaagggttac cagaacatga tgttctagct 2160
      acgaagctga tatcccagaa catgatgttc tagctacgaa gctggtaccc cgcctctgta 2220
      tacgcctatt tttataggtt aatgtcatga taataatggt ttcttagacg tcaggtggca 2280
60     cttttcgggg aaatgtgcgc ggaaccctta tttgtttatt tttctaaata cattcaata 2340
      tgtatccgct catgagacaa taaccctgat aaatgcttca ataatttga aaaaggaaga 2400
      gtatgagtat tcaacatttc cgtgtcgcgc ttattccctt ttttgcggca ttttgccttc 2460

```

```

ctgtttttgc tcaccagaa acgctggtga aagtaaaaga tgctgaagat cagttgggtg 2520
cacgagtggg ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc 2580
ccgaagaacg ttttccaatg atgagcactt ttaaagttct gctatgtggc gcggtattat 2640
cccgtattga cgccggggcaa gagcaactcg gtgcgcgcac acactattct cagaatgact 2700
5  tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca gtaagagaat 2760
tatgcagtgc tgccataacc atgagtata acactgcggc caacttactt ctgacaacga 2820
tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat gtaactcgcc 2880
ttgatcggtt ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga 2940
tgccctgtagc aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag 3000
10  cttcccgcca acaattaata gactggatgg aggcgggataa agttgcagga ccacttctgc 3060
ctcggccctt tccggctggc tggtttattg ctgataaatc tggagccggt gagcgtgggt 3120
ctcggggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct 3180
acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct gagataggtg 3240
cctcactgat taagcattgg taactgtcag accaagttta ctcatatata ctttagattg 3300
15  atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca 3360
tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga 3420
tcaaaggatc ttcttgagat cttttttttc tgcgcgtaat ctgctgcttg caaacaaaaa 3480
aaccaccgct accagcgggt gtttgtttgc cggatcaaga gctaccaact ctttttccga 3540
aggtaactgg cttcagcaga gcgcagatac caaataactgt ccttctagt gtagccgtagt 3600
20  taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg ctaatcctgt 3660
taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttgac tcaagacgat 3720
agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca cagcccagct 3780
tgagcgaac gacctacacc gaactgagat acctacagcg tgagctatga gaaagcgcca 3840
cgcttcccca agggagaaa ggcggacaggt atccggtaag cggcagggtc ggaacaggag 3900
25  agcgcacgag ggagcttcca ggggaaaacg cctggtatct ttatagtcct gtcgggtttc 3960
gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggagg agcctatgga 4020
aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca 4080
tgttctttcc tgctttatcc cctgattctg tggataaccg tattaccgcc tttgagttag 4140
ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagttagc gaggggtacc 4200
30  agaacatgat gttctagcta cgaagctgat atcccagaac atgatgttct agctacgaag 4260
tggttaccac agcgggaagag cgcccaatac gcaaacgcc tctcccgcg cgttggccga 4320
ttcattaatg cagctggcac gacaggtttc ccgactggaa agcgggcagt gagcgcaacg 4380
caattaatgt gagttagctc actcattagg caccacaggc tttacacttt atgcttccgg 4440
ctcgtatggt gtgtggaatt gtgagcggat aacaatttca cacaggaaac agctatgacc 4500
35  atgattacgc caagctctct agagctctag agctctagag ctctagagag cttgcatgcc 4560
ggggtaccag cttcgtagct agaaccatcat gttctgggat atcagcttcg tagctagaac 4620
atcatgttct ggtaccccg tcga 4644

```

```

40  <210> 18
    <211> 933
    <212> PRT
    <213> Homo sapiens

```

```

45  <400> 18
    Met Thr Glu Leu Lys Ala Lys Gly Pro Arg Ala Pro His Val Ala Gly
      1           5           10           15

    Gly Pro Pro Ser Pro Glu Val Gly Ser Pro Leu Leu Cys Arg Pro Ala
      20           25           30

    Ala Gly Pro Phe Pro Gly Ser Gln Thr Ser Asp Thr Leu Pro Glu Val
      35           40           45

55  Ser Ala Ile Pro Ile Ser Leu Asp Gly Leu Leu Phe Pro Arg Pro Cys
      50           55           60

    Gln Gly Gln Asp Pro Ser Asp Glu Lys Thr Gln Asp Gln Gln Ser Leu
      65           70           75           80

60  Ser Asp Val Glu Gly Ala Tyr Ser Arg Ala Glu Ala Thr Arg Gly Ala
      85           90           95

```

Gly Gly Ser Ser Ser Ser Pro Pro Glu Lys Asp Ser Gly Leu Leu Asp
 100 105 110
 5 Ser Val Leu Asp Thr Leu Leu Ala Pro Ser Gly Pro Gly Gln Ser Gln
 115 120 125
 Pro Ser Pro Pro Ala Cys Glu Val Thr Ser Ser Trp Cys Leu Phe Gly
 130 135 140
 10 Pro Glu Leu Pro Glu Asp Pro Pro Ala Ala Pro Ala Thr Gln Arg Val
 145 150 155 160
 Leu Ser Pro Leu Met Ser Arg Ser Gly Cys Lys Val Gly Asp Ser Ser
 165 170 175
 15 Gly Thr Ala Ala Ala His Lys Val Leu Pro Arg Gly Leu Ser Pro Ala
 180 185 190
 20 Arg Gln Leu Leu Leu Pro Ala Ser Glu Ser Pro His Trp Ser Gly Ala
 195 200 205
 Pro Val Lys Pro Ser Pro Gln Ala Ala Ala Val Glu Val Glu Glu Glu
 210 215 220
 25 Asp Gly Ser Glu Ser Glu Glu Ser Ala Gly Pro Leu Leu Lys Gly Lys
 225 230 235 240
 Pro Arg Ala Leu Gly Gly Ala Ala Ala Gly Gly Gly Ala Ala Ala Val
 245 250 255
 30 Pro Pro Gly Ala Ala Ala Gly Gly Val Ala Leu Val Pro Lys Glu Asp
 260 265 270
 35 Ser Arg Phe Ser Ala Pro Arg Val Ala Leu Val Glu Gln Asp Ala Pro
 275 280 285
 Met Ala Pro Gly Arg Ser Pro Leu Ala Thr Thr Val Met Asp Phe Ile
 290 295 300
 40 His Val Pro Ile Leu Pro Leu Asn His Ala Leu Leu Ala Ala Arg Thr
 305 310 315 320
 Arg Gln Leu Leu Glu Asp Glu Ser Tyr Asp Gly Gly Ala Gly Ala Ala
 325 330 335
 45 Ser Ala Phe Ala Pro Pro Arg Ser Ser Pro Cys Ala Ser Ser Thr Pro
 340 345 350
 50 Val Ala Val Gly Asp Phe Pro Asp Cys Ala Tyr Pro Pro Asp Ala Glu
 355 360 365
 Pro Lys Asp Asp Ala Tyr Pro Leu Tyr Ser Asp Phe Gln Pro Pro Ala
 370 375 380
 55 Leu Lys Ile Lys Glu Glu Glu Glu Gly Ala Glu Ala Ser Ala Arg Ser
 385 390 395 400
 Pro Arg Ser Tyr Leu Val Ala Gly Ala Asn Pro Ala Ala Phe Pro Asp
 405 410 415
 60

Phe Pro Leu Gly Pro Pro Pro Pro Leu Pro Pro Arg Ala Thr Pro Ser
 420 425 430

5 Arg Pro Gly Glu Ala Ala Val Thr Ala Ala Pro Ala Ser Ala Ser Val
 435 440 445

Ser Ser Ala Ser Ser Ser Gly Ser Thr Leu Glu Cys Ile Leu Tyr Lys
 450 455 460

10 Ala Glu Gly Ala Pro Pro Gln Gln Gly Pro Phe Ala Pro Pro Pro Cys
 465 470 475 480

15 Lys Ala Pro Gly Ala Ser Gly Cys Leu Leu Pro Arg Asp Gly Leu Pro
 485 490 495

Ser Thr Ser Ala Ser Ala Ala Ala Ala Gly Ala Ala Pro Ala Leu Tyr
 500 505 510

20 Pro Ala Leu Gly Leu Asn Gly Leu Pro Gln Leu Gly Tyr Gln Ala Ala
 515 520 525

Val Leu Lys Glu Gly Leu Pro Gln Val Tyr Pro Pro Tyr Leu Asn Tyr
 530 535 540

25 Leu Arg Pro Asp Ser Glu Ala Ser Gln Ser Pro Gln Tyr Ser Phe Glu
 545 550 555 560

30 Ser Leu Pro Gln Lys Ile Cys Leu Ile Cys Gly Asp Glu Ala Ser Gly
 565 570 575

Cys His Tyr Gly Val Leu Thr Cys Gly Ser Cys Lys Val Phe Phe Lys
 580 585 590

35 Arg Ala Met Glu Gly Gln His Asn Tyr Leu Cys Ala Gly Arg Asn Asp
 595 600 605

Cys Ile Val Asp Lys Ile Arg Arg Lys Asn Cys Pro Ala Cys Arg Leu
 610 615 620

40 Arg Lys Cys Cys Gln Ala Gly Met Val Leu Gly Gly Arg Lys Phe Lys
 625 630 635 640

45 Lys Phe Asn Lys Val Arg Val Val Arg Ala Leu Asp Ala Val Ala Leu
 645 650 655

Pro Gln Pro Leu Gly Val Pro Asn Glu Ser Gln Ala Leu Ser Gln Arg
 660 665 670

50 Phe Thr Phe Ser Pro Gly Gln Asp Ile Gln Leu Ile Pro Pro Leu Ile
 675 680 685

Asn Leu Leu Met Ser Ile Glu Pro Asp Val Ile Tyr Ala Gly His Asp
 690 695 700

55 Asn Thr Lys Pro Asp Thr Ser Ser Ser Leu Leu Thr Ser Leu Asn Gln
 705 710 715 720

60 Leu Gly Glu Arg Gln Leu Leu Ser Val Val Lys Trp Ser Lys Ser Leu
 725 730 735

Pro Gly Phe Arg Asn Leu His Ile Asp Asp Gln Ile Thr Leu Ile Gln
740 745 750

5 Tyr Ser Trp Met Ser Leu Met Val Phe Gly Leu Gly Trp Arg Ser Tyr
755 760 765

Lys His Val Ser Gly Gln Met Leu Tyr Phe Ala Pro Asp Leu Ile Leu
770 775 780

10 Asn Glu Gln Arg Met Lys Glu Ser Ser Phe Tyr Ser Leu Cys Leu Thr
785 790 795 800

Met Trp Gln Ile Pro Gln Glu Phe Val Lys Leu Gln Val Ser Gln Glu
805 810 815

15 Glu Phe Leu Cys Met Lys Val Leu Leu Leu Asn Thr Ile Pro Leu
820 825 830

20 Glu Gly Leu Arg Ser Gln Thr Gln Phe Glu Glu Met Arg Ser Ser Tyr
835 840 845

Ile Arg Glu Leu Ile Lys Ala Ile Gly Leu Arg Gln Lys Gly Val Val
850 855 860

25 Ser Ser Ser Gln Arg Phe Tyr Gln Leu Thr Lys Leu Leu Asp Asn Leu
865 870 875 880

His Asp Leu Val Lys Gln Leu His Leu Tyr Cys Leu Asn Thr Phe Ile
885 890 895

30 Gln Ser Arg Ala Leu Ser Val Glu Phe Pro Glu Met Met Ser Glu Val
900 905 910

Ile Ala Ala Gln Leu Pro Lys Ile Leu Ala Gly Met Val Lys Pro Leu
915 920 925

35 Leu Phe His Lys Lys
930

40 <210> 19
<211> 2970
<212> DNA
<213> Homo sapiens

45 <400> 19

ctgaccagcg ccgccctccc ccgccccga cccaggaggt ggagatccct ccggtccagc 60
cacattcaac acccactttc tcttccctct gccctatat tcccgaacc ccttccctct 120
tcccttttcc ctctccctg gagacggggg aggagaaaag gggagtccag tcgtcatgac 180
50 tgagctgaag gcaaagggtc cccgggctcc ccacgtggcg ggcggcccgc cctccccga 240
ggctcgatcc ccaactgtgt gtcgcccagc cgcaggtccg ttcccgggga gccagacctc 300
ggacaccttg cctgaagttt cggccatacc tatctccctg gacgggtac tcttccctcg 360
gccctgccag ggacaggacc cctccgacga aaagacgcag gaccagcagt cgctgtcgga 420
cgtggagggc gcatattcca gagctgaagc tacaagggt gctggaggca gcagttctag 480
55 tccccagaa aaggacagcg gactgtgga cagtgtcttg gacactctgt tggcgccctc 540
aggtcccggg cagagccaac ccagccctcc cgcctgcgag gtcaccagct cttggtgcet 600
gtttggcccc gaacttcccg aagatccacc ggtgcccc gccacccagc ggggtgtgtc 660
cccgtcatg agccggtccg ggtgcaaggt tggagacagc tccgggacgg cagctgccca 720
taaagtgtg ccccggggcc tgtcaccagc ccggcagctg ctgctcccgc cctctgagag 780
60 ccctcactgg tccggggccc cagtgaagcc gtctccgcag gccgctgcgg tggaggttga 840
ggaggaggat ggctctgagt ccgaggagtc tgcgggtccg cttctgaagg gcaaacctcg 900
ggctctgggt ggcgcggcgg ctggaggagg agccgcggct gtcccgcggg gggcggcagc 960

	aggaggcgctc	gccctgggtcc	ccaaggaaga	ttcccgttc	tcagcgccca	gggtcgccct	1020
	ggtggagcag	gacgcgccga	tggcgcccg	gcgtccccc	ctggccacca	cggtgatgga	1080
	tttcatccac	gtgcctatcc	tgctctcaa	tcacgcctta	ttggcagccc	gcaactcgga	1140
	gctgctggaa	gacgaaagt	acgacggcg	ggccggggct	gccagcgct	ttgccccgcc	1200
5	gcgaggttca	ccctgtgcct	cgccacccc	ggtcgctgta	ggcgacttcc	ccgactgcgc	1260
	gtacccgccc	gacgcgagc	ccaaggacga	cgcgtaccct	ctctatagcg	acttccagcc	1320
	gcccgtctta	aagataaagg	aggaggagga	aggcgcgag	gcctccgcgc	gctccccgcg	1380
	ttcctacctt	gtggccggtg	ccaacccgc	agccttccc	gatttcccgt	tggggccacc	1440
	gcccccgctg	cgcgcgcgag	cgacctcatc	cagacccggg	gaagcggcg	tgacggccgc	1500
10	acccgccagt	gcctcagct	cgtctgcgtc	ctcctcggg	tcgaccctgg	agtgcacct	1560
	gtacaaagcg	gagggcgcg	cgcgccgttc	ggcgccgcg	cctgcgaagg	cctgcgaagg	1620
	gcccggcgcg	agcggtgct	tgctcccgcg	ggacggcctg	ccctccacct	ccgcctctgc	1680
	cgcgcgccgc	ggggcgggcc	cgcgctcta	ccctgcactc	ggcctcaacg	ggctcccga	1740
	gctcggtac	caggccgccc	tgctcaagga	gggcctgccg	caggtctacc	cgcctatct	1800
15	caactacctg	aggccggatt	cagaagccag	ccagagccca	caatacagct	tcgagtcatt	1860
	acctcagaag	atttgtttaa	tctgtgggga	tgaagcatca	ggctgtcatt	atggtgtcct	1920
	tacctgtggg	agctgtaagg	tcttctttaa	gagggcaatg	gaaggcgagc	acaactactt	1980
	atgtgctgga	agaaatgact	gcctcgttga	taaaatccgc	agaaaaaact	gcccagcatg	2040
	tcgccttaga	aagtgtgtc	aggctggcat	ggctccttga	ggtcgaaaat	ttaaaaagtt	2100
20	caataaagtc	agagttgtga	gagcactgga	tgctgttgct	ctcccacagc	cattgggctg	2160
	tccaaatgaa	agccaagccc	taagccagag	attcactttt	tcaccaggtc	aagacatata	2220
	gttgattcca	ccactgatca	acctgttaat	gagcattgaa	ccagatgtga	tctatgcagg	2280
	acatgacaac	acaaaacctg	acacctccag	ttctttgctg	acaagtctta	atcaactagg	2340
	cagagaggca	cttctttcag	tagtcaagtg	gtctaaatca	ttgccagggt	ttcgaaactt	2400
25	acatatgtat	gaccagataa	ctctcattca	gtattcttgg	atgagcttaa	tgggtgttgg	2460
	tctaggatgg	agatcctaca	aacatgtcag	tgggcagatg	ctgtattttg	cacctgatct	2520
	aataactaat	gaacagcgga	tgaagaatc	atcattctat	tcattatgcc	ttaccatgtg	2580
	gcagatccca	caggagtttg	tcaagcttca	agtttagccaa	gaagagttcc	tctgtatgaa	2640
	agtattgtta	cttcttaata	caattccttt	ggaagggtca	cgaagtcaaa	cccagtttga	2700
30	ggagatgagg	tcaagctaca	ttagagagct	catcaaggca	attggtttga	ggcaaaaagg	2760
	agttgtgtcg	agctcacagc	gtttctatca	acttacaaaa	cttcttgata	acttgcata	2820
	tcttgtcaaa	caacttcac	tgtactgctt	gaatacattt	atccagtcct	gggcaactgag	2880
	tgttgaattt	ccagaaatga	tgtctgaagt	tattgtgca	caattaccca	agatattggc	2940
	agggatggtg	aaaccccttc	tctttcataa				2970
35							

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/01368

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/57 C12N15/67 C12N15/85 C12N9/64
C07K14/72 C12Q1/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ²	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 94 28150 A (UNIV MCGILL) 8 December 1994 (1994-12-08) page 5, line 1 - line 11 page 6, line 34 - page 7, line 10 page 6, line 24 - line 28 page 10, line 20 - line 25 page 14, line 14 - line 19 claims 1-11 --- -/--	1,2,6,7, 11,29,30 3-5,8,9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

¹ Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

6 June 2000

Date of mailing of the international search report

26/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/EP 00/01368

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V. BOONYARATANAKORNKIT ET AL.: "High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mamalian cells" MOL. CELL. BIOL., vol. 18, no. 8, August 1998 (1998-08), pages 4471-4487, XP002139580 ASM WASHINGTON, DC,US cited in the application the whole document ---	1,2,7
X	WO 94 17182 A (RES INST OF THE PALO ALTO MEDI ;LEAVITT JOHN C (US)) 4 August 1994 (1994-08-04) page 16, line 30 - line 36 page 17, line 1 - line 3; claims 1-16 ---	1,2,6,7, 11,29,30
X	WO 93 20218 A (CONNAUGHT LAB ;FILMUS JORGE (CA); KLEIN MICHEL (CA)) 14 October 1993 (1993-10-14) the whole document ---	1,2,6,11
Y	WO 94 29471 A (GENETIC THERAPY INC) 22 December 1994 (1994-12-22) the whole document ---	3-5,8,9
A	WO 93 23431 A (BAYLOR COLLEGE MEDICINE) 25 November 1993 (1993-11-25) cited in the application the whole document ---	
A	BEATO M ET AL: "Transcriptional regulation by steroid hormones" STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 4, 1 April 1996 (1996-04-01), pages 240-251, XP004026583 ISSN: 0039-128X the whole document ---	
A	BEATO M: "GENE REGULATION BY STEROID HORMONES" CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 56, no. 3, 10 February 1989 (1989-02-10), pages 335-344, XP000051659 ISSN: 0092-8674 the whole document --- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/01368

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KURACHI S. ET AL: "Regulatory mechanism of human factor IX gene: Protein binding at the Leyden-specific region." BIOCHEMISTRY, (1994) 33/6 (1580-1591). , XP002139581 the whole document ---	
A	CROSSLEY M. ET AL: "Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter." SCIENCE, (1992) 257/5068 (377-379). , XP002139582 the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 00/01368

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9428150 A	08-12-1994	US 5512483 A AU 6791894 A	30-04-1996 20-12-1994
WO 9417182 A	04-08-1994	AU 6087694 A	15-08-1994
WO 9320218 A	14-10-1993	AU 3883393 A BR 9306167 A EP 0633941 A FI 944451 A JP 2701983 B JP 7501456 T NO 943610 A US 5559027 A	08-11-1993 13-01-1998 18-01-1995 26-09-1994 21-01-1998 16-02-1995 30-11-1994 24-09-1996
WO 9429471 A	22-12-1994	EP 0710288 A JP 8511423 T US 5935935 A	08-05-1996 03-12-1996 10-08-1999
WO 9323431 A	25-11-1993	US 5364791 A AU 685054 B AU 4241793 A AU 6065198 A CA 2135644 A EP 0745121 A JP 7509694 T US 5935934 A US 5874534 A	15-11-1994 15-01-1998 13-12-1993 02-07-1998 25-11-1993 04-12-1996 26-10-1995 10-08-1999 23-02-1999